System and method for analyte measurement using dose sufficiency electrodes
- Publication number
- CA2530052C CA2530052C CA 2530052 CA2530052A CA2530052C CA 2530052 C CA2530052 C CA 2530052C CA 2530052 CA2530052 CA 2530052 CA 2530052 A CA2530052 A CA 2530052A CA 2530052 C CA2530052 C CA 2530052C
- Grant status
- Patent type
- Prior art keywords
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes electrical and mechanical details of in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
applying an AC test signal to a first one of the electrodes; determining the presence or absence of a response above a predetermined threshold at the second one of the electrodes, the response indicating that the fluid has occupied substantially all of the measurement zone.
SYSTEM AND METHOD FOR ANALYTE MEASUREMENT' USING DOSE SUFFICIENCY ELECTRODES
The present invention relates to a measurement method and apparatus for use in measuring concentrations of an analyte in a fluid. The invention relates more particularly, but not exclusively, to a method and apparatus which may be used for measuring the concentration of glucose in blood.
BACKGROUND OF THE INVENTION
Measuring the concentration of substances, particularly in the presence of other, confounding substances, is important in many fields, and especially in medical diagnosis. For example, the measurement of glucose in body fluids, such as blood, is crucial to the effective treatment of diabetes.
Diabetic therapy typically involves two types of insulin treatment: basal, and meal-time. Basal insulin refers to continuous, e.g. time-released insulin, often taken before bed. Meal-time insulin treatment provides additional doses of faster acting insulin to regulate fluctuations in blood glucose caused by a variety of factors, including the metabolization of sugars and carbohydrates. Proper regulation of blood glucose fluctuations requires accurate measurement of the concentration of glucose in the blood. Failure to do so can produce extreme complications, including blindness and loss of circulation in the extremities, which can ultimately deprive the diabetic of use of his or her fingers, hands, feet, etc.
Multiple methods are known for measuring the concentration of analytes in a blood sample, such as, for example, glucose. Such methods typically fall into one of two categories: optical methods and electrochemical methods. Optical methods generally involve reflectance or absorbance spectroscopy to observe the spectrum shift in a reagent. Such shifts are caused by a chemical reaction that produces a color change indicative of the concentration of the analyte.
Electrochemical methods generally involve, alternatively, amperometric or coulometric responses indicative of the concentration of the analyte. See, for example, U.S. Patent Nos. 4,233,029 to Columbus, 4,225,410 to Pace, 4,323,536 to Columbus, 4,008,448 to Muggli, 4,654,197 to Lilja et al., 5,108,564 to Szuminsky et al., 5,120,420 to Nankai et al., 5,128,015 to Szuminsky et al., 5,243,516 to White, 5,437,999 to Diebold et at., 5,288,636 to Pollmann et al., 5,628,890 to Carteret al., 5,682,884 to Hill et al., 5,727,548 to Hill et at., 5,997,817 to Crismore et al., 6,004,441 to Fujiwara et al., 4,919,770 to Priedel, et al., and 6,054,039 to Shieh, An important limitation of electrochemical methods of measuring the concentration of a chemical in blood is the effect of confounding variables on the diffusion of analyte and the various active ingredients of the reagent. For example, the geometry and state of the blood sample must correspond closely to that upon which the signal-to-concentration mapping function is based.
The geometry of the blood sample is typically controlled by a sample-receiving portion of the testing apparatus. In the case of blood glucose meters, for example, the blood sample is typically placed onto a disposable test strip that plugs into the meter. The test strip may have a sample chamber (capillary fill space) to define the geometry of the sample. Alternatively, the effects of sample geometry may be limited by assuring an effectively infinite sample size. For example, the electrodes used for measuring the analyte may be spaced closely enough so that a drop of blood on the test strip extends substantially beyond the electrodes in all directions. Ensuring adequate coverage of the measurement electrodes by the sample, however, is an important factor in achieving accurate test results.
This has proven to be problematic in the past, particularly with the use of capillary fill spaces.
Other examples of limitations to the accuracy of blood glucose measurements include variations in blood composition or state (other than the aspect being measured). For example, variations in hematocrit (concentration of red blood cells), or in the concentration of other chemicals in the blood, can effect the signal generation of a blood sample. Variations in the temperature of blood samples is yet another example of a confounding variable in measuring blood chemistry.
Thus, a system and method are needed that accurately measure blood glucose, even in the presence of confounding variables, including variations in temperature, hematocrit, and the concentrations of other chemicals in the blood. A
system and method are also needed to ensure adequate coverage of the measurement electrodes by the sample, particularly in capillary fill devices.
system and method are likewise needed that accurately measure an analyte in a fluid. It is an object of the present invention to provide such a system and method.
SUMMARY OF THE INVENTION
In accordance with the invention, there is provided a method of determining a fill property for a test strip for performing a measurement on a biological fluid comprising: providing a biological fluid test strip comprising a fluid flow intake opening, a fluid flow terminus, a capillary fill chamber extending a length along the test strip from the opening to the terminus, a measurement zone positioned in the fill chamber intermediate the opening and the terminus, and at least two dose sufficiency electrodes having a gap therebetween and positioned intermediate the measurement zone and the terminus; introducing the biological fluid to the opening effective to cause the fluid to flow toward the terminus; applying a test signal having an AC
component to one of the dose sufficiency electrodes; detecting a response or an absence of the response to the test signal at the other of the dose sufficiency electrodes; and determining a dosage fill property of the test strip.
In one form of the invention, a method of determining dose sufficiency in a test strip for performing a measurement on a biological fluid is disclosed, comprising:
providing a biological fluid test strip, comprising: a capillary fill chamber extending a length along the test strip from an intake opening to a terminus, a reagent disposed in the capillary fill chamber between the opening and the terminus, the reagent defining a measurement zone, and at least two dose sufficiency electrodes defining a gap therebetween and in operative communication with the capillary fill chamber, the electrodes located between the measurement zone and the terminus; applying the biological fluid to the opening, whereby the fluid flows from the opening toward the terminus, the flow including a flow front selected from one of a concave, a convex and a substantially flat flow front; applying a test signal to a first one of the electrodes; determining the presence or absence of a response above a predetermined threshold at the second one of the electrodes, the response indicating that the fluid has occupied substantially all of the measurement zone regardless of whether the flow front is concave, convex or substantially flat.
In another form of the invention, a method of determining dose sufficiency in a test strip for performing a measurement on a biological fluid is disclosed, comprising: providing a biological fluid test strip, comprising: a fluid flow intake opening, a fluid flow terminus, a reagent disposed on the test strip between the opening and the terminus, the reagent defining a measurement zone, and at least two dose sufficiency electrodes defining a gap therebetween and located between the measurement zone and the terminus; applying the biological fluid to the opening, whereby the fluid flows from the opening toward the terminus, the flow including a flow front selected from one of a concave, a convex and a substantially flat flow front; applying a test signal to a first one of the electrodes;
determining the presence or absence of a response above a predetermined threshold at the second one of the electrodes, the response indicating that the fluid has occupied substantially all of the measurement zone regardless of whether the flow front is concave, convex or substantially flat.
In another form of the invention, a method of determining a dose sufficiency in a test strip for performing a measurement on a biological fluid is disclosed, 5 comprising: providing a biological fluid test strip comprising: a capillary fill chamber extending a length along the test strip, at least two measurement electrodes in operative communication with the chamber, and at least two dose sufficiency electrodes in operative communication with the chamber; applying the biological fluid to the test strip; applying a dose sufficiency test signal having an AC component to one of the dose sufficiency electrodes; and measuring a response to the dose sufficiency test signal at the other of the dose sufficiency electrodes.
In another form of the invention, a method of determining a fill sufficiency in test strip for performing a measurement on a biological fluid is disclosed, comprising: providing a biological fluid test strip including a capillary fill chamber extending a length along the test strip from an intake opening to a terminus, a measurement zone in the chamber positioned intermediate the opening and the terminus, and at least two dose sufficiency electrodes in operative communication with the chamber the electrodes positioned intermediate the measurement zone and the terminus; introducing the biological fluid to the opening effective to cause the fluid to flow toward the terminus whereby the chamber is filled; applying a test signal having an AC component to one of the dose sufficiency electrodes; and detecting a response or an absence of the response to the test signal at the other of the dose sufficiency electrodes effective to indicate the fill sufficiency of the biological fluid.
In another form of the invention, a method of determining dosage fill level in a test strip for performing a measurement on a biological fluid is disclosed, comprising: providing a biological fluid test strip including a capillary fill chamber extending a length along the test strip from an opening to a terminus, and at least two dose sufficiency electrodes in operative communication with the chamber the dose sufficiency electrodes positioned to define a gap between one another;
dosing the test strip with a biological fluid effective to cause the biological fluid to begin to fill the chamber; applying a signal having an AC component to one of the dose sufficiency electrodes; measuring a response to the signal at the other of the dose sufficiency electrodes; determining the dosage fill level based upon the response.
In another form of the invention, a method of determining a fill level of a biological fluid in a test strip for performing a measurement on the fluid is disclosed, comprising: providing a test strip including a capillary fill chamber extending a length along the test strip from an opening to a terminus, and at least two dose sufficiency electrodes in operative communication with the chamber the dose sufficiency electrodes positioned to define a gap between one another;
introducing the biological fluid to the opening effective to cause the fluid to flow toward the terminus whereby the chamber is filled; applying a test signal having an AC component to one of the dose sufficiency electrodes; and measuring a response to the signal at the other of the dose sufficiency electrodes; determining the fill level of the biological fluid based upon the response wherein the response varies in relation to the fill level.
In another form of the invention, a method of determining dosage fill rate in a biological fluid test strip is disclosed, comprising: providing a biological fluid test strip including a capillary fill chamber extending a length along the test strip from an opening to a terminus, and at least two dose sufficiency electrodes in operative communication with the chamber the dose sufficiency electrodes positioned to define a gap between one another; dosing the test strip with a biological fluid effective to cause the biological fluid to begin to fill the chamber;
applying a signal having an AC component to one of the dose sufficiency electrodes; measuring a first response to the signal at the other of the dose sufficiency electrodes at a first time; measuring a second response to the signal at the other of the dose sufficiency electrodes at a second time; and determining a rate at which the biological fluid fills the chamber based at least in part upon the first response and the second response.
In another form of the invention, a test strip for performing a measurement on a biological fluid is disclosed, comprising: a capillary fill chamber extending a length along the test strip from an opening to a terminus; at least two measurement electrodes in operative communication with the chamber; and at least two dose sufficiency electrodes in operative communication with the chamber; wherein the dose sufficiency electrodes have first edges essentially parallel to the length of the capillary chamber and second edges essentially perpendicular to the length of the capillary fill chamber with the first edges being of greater length than the second edges.
In another form of the invention, a test strip for performing a measurement on a biological fluid is disclosed, comprising: a capillary fill chamber extending a length along the test strip from an opening to a terminus; a measurement zone in the chamber positioned intermediate the opening and the terminus, and at least two dose sufficiency electrodes in operative communication with the chamber the electrodes positioned intermediate the measurement zone and the terminus;
wherein the dose sufficiency electrodes have a first axis essentially parallel to the length of the capillary chamber and a second axis essentially perpendicular to the length of the capillary fill chamber with the first axis being of greater length than the second axis.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will be further described, by way of example only, with reference to the accompanying drawings, in which:
Fig. 1 is a diagram of a first embodiment excitation signal suitable for use in a system and method according to the present invention, having a serially-applied AC component and DC component.
Fig. 2 is a diagram of a second embodiment excitation signal suitable for use in a system and method according to the present invention, having a simultaneously-applied AC component and DC component.
Figs. 3A-B illustrate a first embodiment test strip of the present invention.
Fig. 4 is a diagram of an excitation signal utilized in the test of Example 1.
Fig. 5 is a plot of the correlation coefficient r2 (glucose vs. DC current) versus Read Time for the test of Example 1 with no incubation time.
Fig. 6 is a plot of the correlation coefficient r2 (glucose vs. DC current) versus Read Time for the test of Example 1 with varying incubation time.
Fig. 7 is a plot of AC admittance versus hematocrit for the test of Example 2.
Fig. 8 is a plot of uncompensated DC current versus glucose for the test of Example 2.
Fig. 9 is a plot of the predicted glucose response versus the actual glucose response for the test of Example 2.
Fig. 10 is a diagram of an excitation signal utilized in the test of Example 3.
Fig. 11 is a plot of the AC phase angle versus reference glucose for the test of Example 3.
Fig. 12 is a plot of the predicted glucose response versus the actual glucose response for the test of Example 3.
Fig. 13 is a diagram of an excitation signal utilized in the test of Example 4.
Fig. 14 is a plot of AC admittance versus hematocrit (parametrically displayed with temperature) for the test of Example 4.
Fig. 15 is a plot of the uncompensated DC response versus actual glucose for the test of Example 4.
Fig. 16 is a plot of the predicted glucose response versus actual glucose response for the test of Example 4.
Figs. 17A-B illustrate a second embodiment test strip of the present invention.
Fig. 18 is a plot parametrically illustrating the correlation coefficient r2 between the DC current response and glucose level as Read Time varies for three combinations of temperature and hematocrit in the test of Example 5.
Fig. 19 is a diagram of the excitation signal utilized in the test of Example 5.
Fig. 20 is a plot of AC admittance versus hematocrit as temperature is parametrically varied in the test of Example 5.
Fig. 21 is a plot of AC admittance phase angle versus hematocrit as temperature is parametrically varied in the test of Example 5.
Fig. 22 is a plot of the uncompensated DC response versus actual glucose 5 for the test of Example 5.
Fig. 23 is a plot of the predicted glucose response versus actual glucose response for the test of Example 5.
10 Fig. 24 is a diagram of the excitation signal utilized in the test of Example 6.
Fig. 25 is a plot of the correlation coefficient r2 between hematocrit and DC
response current plotted against hematocrit in the test of Example 6.
Fig. 26 is a plot of AC admittance phase angle versus hematocrit for the test of Example 6.
Fig. 27 is a plot of the uncompensated DC response versus actual glucose for the test of Example 6.
Fig. 28 is a plot of the compensated DC response versus actual glucose for a 1.1 second Total Test Time of Example 6.
Fig. 29 is a plot of the compensated DC response versus actual glucose for a 1.5 second Total Test Time of Example 6.
Fig. 30 is a plot of the compensated DC response versus actual glucose for a 1.9 second Total Test Time of Example 6.
Fig. 31 is a table detailing the heights and widths of the capillary fill channels used in the test devices of Example 8, as well as schematic diagrams of convex and concave sample flow fronts in a capillary fill space.
Figs. 32A-C are schematic plan views of a test strip illustrating the potential for biased measurement results when a concave flow front encounters a prior art dose sufficiency electrode.
Fig. 33 is a schematic plan view of a test strip of the present invention having a pair of perpendicular dose sufficiency electrodes that are independent from the measurement electrodes.
Figs. 34A-B are schematic plan views of the test strip of FIG. 33 containing samples with convex and concave flow fronts, respectively.
Figs. 35A-B are schematic plan views of a test strip of the present invention having a pair of parallel dose sufficiency electrodes that are independent from the measurement electrodes.
Fig. 36 is a schematic plan view of the test strip of Fig. 35, schematically illustrating the electric field lines that communicate between the electrode gap when the electrodes are covered with sample.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings, and specific language will be used to describe that embodiment. It will nevertheless be understood that no limitation of the scope of the invention is intended. Alterations and modifications in the illustrated device, and further applications of the principles of the invention as illustrated therein, as would normally occur to one skilled in the art to which the invention relates are contemplated, are desired to be protected. In particular, although the invention is discussed in terms of a blood glucose meter, it is contemplated that the invention can be used with devices for measuring other analytes and other sample types.
Such alternative embodiments require certain adaptations to the embodiments discussed herein that would be obvious to those skilled in the art.
Reference may be made to US 2005/0023137, US 2005/0023152, US 2005/0013731 and US 2005/0019212.
A system and method according to the present invention permit the accurate measurement of an analyte in a fluid. In particular, the measurement of the analyte remains accurate despite the presence of interferants, which would otherwise cause error. For example, a blood glucose meter according to the present invention measures the concentration of blood glucose without error that is typically caused by variations in the temperature and the hematocrit level of the sample. The accurate measurement of blood glucose is invaluable to the prevention of blindness, loss of circulation, and other complications of inadequate regulation of blood glucose in diabetics. An additional advantage of a system and method according to the present invention is that measurements can be made much more rapidly and with much smaller sample volumes, making it more convenient for the diabetic person to measure their blood glucose. Likewise, accurate and rapid measurement of other analytes in blood, urine, or other biological fluids provides for improved diagnosis and treatment of a wide range of medical conditions.
It will be appreciated that electrochemical blood glucose meters typically (but not always) measure the electrochemical response of a blood sample in the presence of a reagent. The reagent reacts with the glucose to produce charge carriers that are not otherwise present in blood. Consequently, the electrochemical response of the blood in the presence of a given signal is intended to be primarily dependent upon the concentration of blood glucose. Secondarily, however, the electrochemical response of the blood to a given signal is dependent upon other factors, including hematocrit and temperature. See, for example, U.S. Patents Nos.
5,243,516; 5,288,636; 5,352,351; 5,385,846; and 5,508,171, which discuss the confounding effects of hematocrit on the measurement of blood glucose.
In addition, certain other chemicals can influence the transfer of charge carriers through a blood sample, including, for example, uric acid, bilirubin, and oxygen, thereby causing error in the measurement of glucose.
A preferred embodiment system and method for measuring blood glucose according to the present invention operates generally by using the signal-dependence of the contribution of various factors to the impedance (from which admittance and phase angle may be derived) of a blood sample. Because the contribution of various factors to the impedance of a blood sample is a function of the applied signal, the effects of confounding factors (that is, those other than the factors sought to be measured) can be substantially reduced by measuring the impedance of the blood sample to multiple signals. In particular, the effects of confounding factors, (primarily temperature and hematocrit, but also including chemical interferants such as oxygen), contribute primarily to the resistivity of the sample, while the glucose-dependent reaction contributes primarily to the capacitance. Thus, the effects of the confounding factors can be eliminated by measuring the impedance of the blood sample to an AC excitation, either alone or in combination with a DC excitation. The impedance (or the impedance derived admittance and phase information) of the AC signal is then used to correct the DC
signal or AC derived capacitance for the effects of interferants.
It will be appreciated that measurements at sufficiently high AC
frequencies are relatively insensitive to the capacitive component of the sample's impedance, while low frequency (including DC) measurements are increasingly (with decreasing frequency) sensitive to both the resistive and the capacitive components of the sample's impedance. The resistive and capacitive components of the impedance can be better isolated by measuring the impedance at a larger number of frequencies. However, the cost and complexity of the meter increases as the number of measurements increases and the number of frequencies that need to be generated increases. Thus, in the presently preferred embodiment, the impedance may be measured at greater than ten frequencies, but preferably at between two and ten frequencies, and most preferably at between two and five frequencies.
As used herein, the phrase "a signal having an AC component" refers to a signal which has some alternating potential (voltage) portions. For example, the signal may be an "AC signal" having 100% alternating potential (voltage) and no DC portions; the signal may have AC and DC portions separated in time; or the signal may be AC with a DC offset (AC and DC signals superimposed).
Stele Measurement with Successive AC and DC Signals Figure 1 illustrates a preferred embodiment excitation signal suitable for use in a system and method according to the present invention, indicated generally at 100, in which DC excitation and four frequencies of AC excitation are used.
Figure 1 also illustrates a typical response to the excitation when the excitation is applied to a sample of whole blood mixed with an appropriate reagent, the response indicated generally at 102. A relatively high frequency signal is applied, starting at time 101. In the preferred embodiment the frequency is between about 10kHz and about 20kHz, and has an amplitude between about 12.4mV and about 56.6mV. A frequency of 20kHz is used in the example of FIG. 1. Those skilled in the art will appreciate that these values may be optimised to various parameters such as cell geometry and the particular cell chemistry.
At time 110 a test strip is inserted into the meter and several possible responses to the insertion of the test strip into the glucose meter are shown.
It will be appreciated that the test strip may also be inserted before the excitation signal 5 100 is initiated (i.e. before time 101); however, the test strip itself may advantageously be tested as a control for the suitability of the strip. It is therefore desirable that the excitation signal 100 be initiated prior to test strip insertion. For example, relatively large current leakage, as shown at 112, may occur if the strip is wet, either because the test strip was pre-dosed, or due to environmental moisture.
10 If the test strip has been pre-dosed and permitted to largely or completely dry out, an intermediate current leakage may occur, as shown at 114. Ideally, insertion of the test strip will cause no or negligible leakage current due to an expected absence of charge carriers between the test electrodes, as shown at 116. Measured current leakage above a predetermined threshold level will preferably cause an error 15 message to be displayed and prevent the test from continuing.
Once a suitable test strip has been inserted, the user doses the strip, as shown at time 120. While the blood sample is covering the electrodes the current response will rapidly increase, as the glucose reacts with the reagent and the contact area increases to maximum. The response current will reach a stable state, which indicates the impedance of the sample at this frequency. Once this measurement is made and recorded by the test meter, the excitation frequency is then stepped down to about 10kHz in the preferred embodiment, as shown at time 130. Another measurement is made and recorded by the test meter, and the frequency is stepped down to about 2kHz in the preferred embodiment, as shown at 140. A third measurement is made and recorded by the test meter at this frequency. A fourth measurement is made at about 1kHz in the preferred embodiment, as shown at 150. In the preferred embodiment, measurements are taken at regular intervals (e.g. 10 points per cycle). It will be appreciated that the stable state response may be measured as current or voltage (preferably both magnitude and phase) and the impedance and/or admittance can be calculated therefrom. Although the present specification and claims may refer alternately to the AC response as impedance or admittance (magnitude and/or phase), resistance, conductivity, current or charge, and to the DC response as current, charge, resistance or conductivity, those skilled in the art will recognize that these measures are interchangeable, it only being necessary to adjust the measurement and correction mathematics to account for which measure is being employed. In the preferred embodiment, the test meter applies a voltage to one electrode and measures the current response at the other electrode to obtain both the AC and DC
In certain alternative embodiments measurements are made at fewer or more frequencies. Preferably measurements are made at at least two AC
frequencies at least an order of magnitude apart. If more than two AC
frequencies are used, then it is preferable that the highest and lowest frequencies be at least an order of magnitude apart.
It will be appreciated that various waveforms may be used in an AC signal, including, for example, sinusoidal, trapezoidal, triangle, square and filtered square.
In the presently preferred embodiment the AC signal has a filtered square waveform that approximates a sine wave. This waveform can be generated more economically than a true sine wave, using a square wave generator and one or more filters.
Once all four AC measurements are made, the signal is preferably briefly reduced to zero amplitude, as shown at 160. The DC excitation is then begun, as shown at 170. The amplitude of the DC excitation is advantageously selected based on the reagent being used, in order to maximise the resulting response or response robustness. For example, if ferricyanide is being used in a biamperometry system, the DC amplitude is preferably about 300mV. For another example, if a nitrosoaniline derivative is being used in a biamperometry system, the DC
amplitude is preferably about 500-550mV. In the alternative, if a third reference electrode is used, the DC applitude is preferably 600 mV (versus the silver/silver chloride reference electrode) for ferricyanide, and 40-100 mV (versus the silver/silver chloride reference electrode) for nitrosoaniline derivative.
excitation, measurements are preferably made at a rate of 100 pts/sec. The current response will follow a decay curve (known as a Cottrell curve), as the reaction is limited by the diffusion of unreacted glucose next to the working electrode.
The resulting stable-state amplitude (measured or projected) is used to determine a glucose estimation of the sample, as is known in the art. A corrected estimation is then determined that corresponds more closely to the concentration of glucose in the blood, by using the impedance of the sample to the AC signal to correct for the effects of interferants, as explained in greater detail hereinbelow.
It will be appreciated that a method according to the present invention may also be used to measure the concentration of other analytes and in other fluids. For example, a method according to the present invention may be used to measure the concentration of a medically significant analyte in urine, saliva, spinal fluid, etc.
Likewise, by appropriate selection of reagent a method according to the present invention may be adapted to measure the concentration of, for example, lactic acid, hydroxybutyric acid, etc.
Sample Measurement with Simultaneously Applied AC and DC Si nals It will be appreciated that at least some of the applied DC and AC
components can also be applied simultaneously. Figure 2 illustrates an excitation signal suitable for use in a system and method according to the present invention in which some of the AC and DC components are applied simultaneously, indicated generally at 200, and having corresponding events numbered correspondingly to Figure 1 (so, for example, the signal 200 is initiated at time 201, and a strip is inserted at time 210, etc.). As with the signal 100, the signal 200 has a frequency of about 10-20kHz and an amplitude of about 12.4-56.6mV. However, after the strip has been dosed, as shown at time 220, a DC offset is superimposed, as shown at 270. Typical AC and DC responses are shown in Figure 2. The AC and DC
responses are measured simultaneously and mathematically deconvoluted and used to determine the, impedance (admittance magnitude and phase) and the amperometric or coulometric response.
A system for measuring blood glucose according to the present invention advantageously employs a blood glucose meter and test strips generally similar to those used in prior art systems, such as those commercially available from Roche Diagnostics, and such as are described in U.S. Patents Nos. 6,270,637; and 5,989,917. These test strips provide apparati having a sample cell in which the blood sample is received for testing, and electrodes disposed within the sample cell through which the excitation signal is provided and the measurements are made. Those skilled in the art will appreciate that these test strips and meters may advantageously be used for the measurement of glucose in blood, but that other apparati may be more suitable for the measurement of other analytes or other biological fluids when practising the present invention.
A suitable glucose meter may be adapted from such known meters by the addition of electronic circuitry that generates and measures signals having AC
and DC components, such as those described hereinabove, and by being programmed to correct the DC measurement using the AC measurement(s), as described in greater detail hereinbelow. It will be appreciated that the specific geometry and chemistry of the test strips can cause variations in the relationships between the concentration of glucose, hematocrit, and temperature, and the impedance of a sample. Thus, a given combination of test strip geometry and chemistry must be calibrated, and the meter programmed with the corresponding algorithm. The present invention comprehends the application of excitation signals in any order and combination. For example, the present invention comprehends the application of 1) AC only, 2) AC then DC, 3) AC then DC then AC, 4) DC then AC, and 5) AC with a DC offset, just to name a few of the possible permutations.
The use of the complex AC impedance measurement data to correct for the effects of interferants on the DC measurement is advantageously illustrated by the following series of examples. These examples illustrate how the principles of the present invention can facilitate improvements in accuracy and test speed when measuring the concentration of an analyte in a test specimen. Although the following examples deal with correcting for the interfering effects of hematocrit and temperature on blood glucose determinations, those skilled in the art will recognize that the teachings of the present invention are equally useful for correcting for the effects of other interferants in both blood glucose measurements and in the measurement of other analytes. Furthermore, the present specification and claims refer to steps such as "determine the hematocrit value" and "determine the temperature," etc. To use the hematocrit value as an example, it is intended that such statements include not only determining the actual hematocrit value, but also a hematocrit correction factor vs. some nominal point. In other words, the process may never actually arrive at a number equal to the hematocrit value of the sample, but instead determine that the sample's hematocrit differs from a nominal value by a certain amount. Both concepts are intended to be covered by statements such as "determine the hematocrit value."
Example 1: DC-Only Measurement Dose Response Study The measurements made in Example 1 were achieved using the test strip illustrated in Figures 3A-B and indicated generally at 300. The test strip 300 includes a capillary fill space containing a relatively thick film reagent and working and counter electrodes, as described in U.S. Patent No. 5,997,817.
The test strip 300 is commercially available from Roche Diagnostics Corporation (Indianapolis, IN) under the brand name Comfort Curve . The ferricyanide reagent used had the composition described in Tables I and II.
Table I: Reagent Mass Composition - Prior to Dispense and Drying Component % w/w Mass for 1kg solid Polyethylene oxide (300kDa) 0.8400% 8.4000g solid Natrosol 250M 0.0450% 0.4500g solid Avicel RC-591F 0.5600% 5.6000g solid Monobasic potassium phosphate (annhydrous) 1.2078% 12.0776g solid Dibasic potassium phosphate (annhydrous) 2.1333% 21.3327g solid Sodium Succinate hexahydrate 0.6210% 6.2097g solid Quinoprotein glucose dehydrogenase 0.1756% 1.7562g (EnzC#: 22.214.171.124) solid PQQ 0.0013% 0.0125g solid Trehalose 2.0000% 20.0000g solid Potassium Ferricyanide 5.9080% 59.0800g solid Triton X-100 0.0350% 0.3500g solvent Water 86.4731% 864.7313g % Solids 0.1352687 Target pH 6.8 Specific Enzyme Activity Used (U/mg) 689 DCIP
5 Dispense Volume per Sensor 4.6 mg Table II: Reagent Layer Composition - After Drying Component % w/w Mass per Sensor solid Polyethylene oxide (300kDa) 6.2099% 38.6400ug solid Natrosol 250M 0.3327% 2.0700ug solid Avicel RC-591F 4.1399% 25.7600ug solid Monobasic potassium phosphate (annhydrous) 8.9286% 55.5568ug solid Dibasic potassium phosphate (annhydrous) 15.7706% 98.1304ug solid Sodium Succinate hexahydrate 4.5906% 28.5646ug solid Quinoprotein glucose dehydrogenase 1.2983% 8.0784ug (EnzC#: 126.96.36.199) solid PQQ 0.0093% 0.0576ug solid Trehalose 14.7854% 92.0000ug solid Potassium Ferricyanide 43.6760% 271.7680ug solid Triton X-100 0.2587% 1.6100ug In the measurements, blood samples were applied to test strip 300 and the excitation potentials illustrated in Figure 4 were applied to the electrodes.
The excitation comprised a 2 kHz 40 mV,. (56.56 mV peak) AC signal applied between 0 seconds and approximately 4.5 seconds after sample application, followed by a 300 mV DC signal applied thereafter. For the calculations of this example, however, only the DC measurement data was analyzed.
In order to determine the minimum needed DC excitation time, a "dose response" study was performed, in which glycollyzed (glucose depleted) blood was divided into discrete aliquots and controlled levels of glucose were added to obtain five different known levels of glucose in the blood samples. The resulting DC
current profile was then examined as two parameters were varied. The first parameter was the Incubation Time, or the time between the detection of the blood sample being applied to the test strip 300 and the application of the DC
potential to the test strip 300. The second parameter to be varied was the Read Time, or the time period after application of the DC potential and the measurement of the resulting current. The length of time between detection of the blood sample being applied to the test strip to the taking of the last measurement used in the concentration determination calculations is the Total Test Time. In this study, therefore, the sum of the Incubation Time and the Read Time is the Total Test Time. The results of this study are illustrated in Figures 5 and 6.
In Figure 5, the DC response was measured with no incubation time (Read Time = Total Test Time). Figure 5 plots the correlation coefficient r2 versus Read Time. As can be seen, the correlation exceeds 0.95 within 1.0 second. In Figure 6, the DC response was measured with varying Incubation Time. When an Incubation Time is provided (even an Incubation Time as short as two (2) seconds), the r2 value rose to over 0.99 in 0.5 seconds or less after application of the DC potential.
The barrier to implementation of such fast test times in a consumer glucose test device, however, is the variation from blood sample to blood sample of the level of interference from the presence of blood cells in the sample. The hematocrit (the percentage of the volume of a blood sample which is comprised of cells versus plasma) varies from individual to individual. The interference effect of hematocrit on such measurements is fairly complex. In the tests of Example 1, however, all samples contained the same level of hematocrit. With no variable hematocrit influence at the different glucose levels, the hematocrit term cancels out in the correlation figures.
Example 2: Combined AC and DC Measurement of Capillary Blood Samples The measurements made in Example 2 were also achieved using the test strip illustrated in Figures 3A-B and indicated generally at 300. As described above, the test strip 300 includes a capillary fill space containing a relatively thick film reagent and working and counter electrodes, as described in U.S. Patent No.
5,997,817, In the measurements, capillary blood samples from various fingerstick donors were applied to test strip 300 and the excitation potentials illustrated in Figure 4 were applied to the electrodes. The excitation comprised a 2 kHz 40 mV. AC signal applied between 0 seconds and approximately 4.5 seconds after sample application, followed by a 300 mV DC signal applied thereafter.
In this Example 2, the AC response of the sample was derived as admittance (the inverse of impedance). The admittance response is proportionate to the hematocrit level of the sample in a temperature dependent manner. The relationship between admittance, hematocrit and testing temperature is illustrated in Figure 7. The data used for the admittance charted in Figure 7 is the last admittance measurement made for each sample during the AC portion of the excitation illustrated in Figure 4.
Regression analysis of this data allows admittance, hematocrit and temperature to be related according to the following formula:
Hest = co + ctY2xxz + c2dT (Equation 1) Using this relationship to predict the blood hematocrit is accomplished using test temperature data reported by the temperature sensor in the meter and the measured admittance. In Equation 1, co, ct and c2 are constants, dT is the deviation in temperature from a center defined as "nominal" (24 C for example), and Hest is the estimated deviation in hematocrit from a similar "nominal" value. For the present purposes, the actual hematocrit value is not necessary, and it is generally preferred to produce a response which is proportionate but centers around a nominal hematocrit. Thus, for a 70% hematocrit, the deviation from a nominal value of 42% would be 28%, while conversely for a 20% hematocrit the deviation from that same nominal value would be -22%.
By using the AC admittance measurement to estimate the hematocrit level using Equation 1, the accuracy of the DC glucose response can be greatly improved by combining the estimated hematocrit, temperature and DC response to correct for the hematocrit interference in the DC response as follows:
PRED = (ao + hctiHest + hct2Hest2 + tau1dT + tau2dT) (Equation 2) + (a1DC)(1 + hct3Hest + hct4Hest2)(1 + tau3dT + tau4dT2) where DC is the measured glucose current response to the applied DC signal and PRED is the compensated (predicted) glucose response corrected for the effects of hematocrit and temperature. The constants (ao, hct1, hct2, taut, taut, a1, hct3, hct4, tau3 and tau4) in Equation 2 can be determined using regression analysis, as is known in the art.
Figure 8 illustrates the uncompensated 5.5 second DC glucose response of all of the capillary blood samples as temperature varies (ignoring the AC
measurement data). As will be appreciated, there is a wide variation in the DC
current response as temperature and hematocrit vary. Figure 9 illustrates the correlation between the actual blood glucose level of the sample versus the predicted response using Equation 2. As can be seen, when the DC response is compensated for hematocrit levels using the AC response data, r2 values of 0.9404 to 0.9605 are achieved with a Total Test Time of 5.5 seconds.
Example 3: Use of AC Phase Angle to Estimate Blood Glucose Levels and Hematocrit The measurements made in Example 3 were also achieved using the test strip illustrated in Figures 3A-B and indicated generally at 300. As described above, the test strip 300 includes a capillary fill space containing a relatively thick film reagent and working and counter electrodes, as described in U.S. Patent No.
5,997,817. Because hematocrit levels from capillary blood samples typically vary only between 30% - 50%, spiked venous blood samples having a hematocrit range from 20% - 70% were used for this Example 3. Five levels of glucose, temperature (14, 21, 27, 36 and 42 C) and hematocrit (20, 30, 45, 60 and 70%) were independently varied, producing a covariance study with 125 samples.
In the measurements, blood samples were applied to test strip 300 and the excitation potentials illustrated in Figure 10 were applied to the electrodes.
The excitation comprised a 2 kHz AC signal for approximately 4.1 seconds, a 1 kHz AC signal for approximately 0.1 seconds, and a 200 Hz signal for approximately 0.1 seconds. All three AC signals had an amplitude of 56.56 mV peak. No DC
excitation was used in this example. The Total Test Time was 4.3 seconds from sample application time.
It was found that another component of the AC response, the phase angle (particularly at lower frequencies, such as 200 Hz in this Example 3), is also a function of the sample glucose level in the case of this test strip and reagent. This relationship is demonstrated in Figure 11, where the AC phase angle for each of the three test frequencies is plotted versus the reference glucose level.
Regression analysis for each of the three frequencies produces AC phase angle-to-reference glucose level r2 correlation values of 0.9114 at 2 kHz, 0.9354 at 1 kHz, and 0.9635 at 200 Hz. The present invention therefore comprehends the use of the AC phase angle to measure glucose levels. The AC excitation frequency producing the measured phase angle is preferably 2 kHz or below, more preferably I kHz or below, and most preferably 200 Hz or below, but not including DC excitation.
The linearized relationship between the 200 Hz phase angle response and the blood glucose level is as follows:
5 Peff = 020O H7 / r )' (Equation 3) where Peff is the effective phase, which is proportional to glucose, the terms r and y are constants, and I is the measured AC phase angle.
10 Using the same approach to compensate for temperature and hematocrit as used in Example 1 above (see Equations 1 and 2) produced a predictive algorithm as follows:
PRED = (ao + hctiHest + hct2H,t2 + tauldT + tau2dT2) (Equation 4) 15 + (a1Peff)(1 + hct3Hest + hct4HeSt2)(1 + tau3dT + tau4dT2) The resulting compensated (predicted) response PRED versus glucose for the 125 blood samples (each tested with eight test strips) is shown in Figure 12. The r2 correlation of the FRED response vs. known glucose level, where all temperatures 20 and all hematocrits are combined, is 0.9870. This Example 3 demonstrates again the value of AC measurements for compensating for interferants that reduce the accuracy of blood glucose measurements. Using an existing commercially available sensor, the present invention yields a 4.3 second Total Test Time with an overall r2 of 0.9870.
25 It was also determined that AC phase angle measurements can produce hematocrit level measurements that are almost immune to the effects of temperature variation. In another covariant study of 125 samples (five glucose concentrations, five hematocrit concentrations and five temperatures), each of the samples was tested using an excitation profile of 20 kHz, 10kHz, 2 kHz, 1kHz and DC. The AC phase angle at various frequencies was related to glucose, hematocrit and temperature using linear regression to determine the coefficients of the following formula at each of the four AC frequencies:
Phase = co + c1Glu + c2HCT + c3Temp (Equation 5) where Glu is the known glucose concentration, HCT is the known hematocrit concentration and Temp is the known temperature.
The determined coefficients revealed that the temperature coefficient (c3) was essentially zero at 20 kHz and 10 kHz, cancelling temperature from the equation at these frequencies. Furthermore, the glucose coefficient (cl) is essentially zero at all of the AC frequencies because, as explained hereinabove, the higher frequency AC impedance measurements are largely unaffected by glucose levels and are therefore useful for measuring the levels of interfering substances. It was therefore found that the hematocrit level could be determined independent of temperature and glucose level using only the AC phase angle measurements. In a preferred embodiment, the hematocrit may be measured using the phase angle data from all four measured frequencies:
ILA = Co + C1I2okHz + C20IOkHz + c3 )2kHz + c4(1)1 (Equation 6) Those skilled in the art will recognise that that the coefficients can be empirically determined for any particular test strip architecture and reagent chemistry.
The present invention therefore may be used to estimate hematocrit using only AC
phase angle measurements preferably made at at least one AC frequency, more preferably made at at least two AC frequencies, and most preferably made at at least four AC frequencies.
Example 4: Combined AC and DC Measurement Using Nitrosoaniline Resent The measurements made in Example 4 were also achieved using the test strip illustrated in Figures 3A-B and indicated generally at 300. As described above, the test strip 300 includes a capillary fill space containing a relatively thick film reagent and working and counter electrodes, as described in U.S..Patent No.
5,997,817. The test strip was modified from that described in U.S. Patent No. 5,997,817, however, by the use of a different reagent. The nitrosoaniline reagent used had the composition described in Tables III and IV.
Table III: Reagent Mass Composition - Prior to Dispense and Drying Component % w/w Mass for 1kg solid Polyethylene oxide (300kDa) 0.8054% 8.0539g solid Natrosol 250M 0.0470% 0.4698g solid Avicel RC-591F 0.5410% 5.4104g solid Monobasic potassium phosphate (annhydrous) 1.1437% 11.4371g solid Dibasic potassium phosphate (annhydrous) 1.5437% 15.4367g solid Disodium Succinate hexahydrate 0.5876% 5.8761g solid Potassium Hydroxide 0.3358% 3.3579g solid Quinoprotein glucose dehydrogenase 0.1646% 1.6464g (EnzC#: 188.8.131.52) solid PQQ 0.0042% 0.0423g solid Trehalose 1.8875% 18.8746g solid Mediator 31.1144 0.6636% 6.6363g solid Triton X-100 0.0327% 0.3274g solvent Water 92.2389% 922.3888g % Solids 0.1352687 Target pH 6.8 Specific Enzyme Activity Used (U/mg) 689 DCIP
Dispense Volume per Sensor 4.6 mg Table IV: Reagent Layer Composition - After Drying Component % w/w Mass per Sensor solid Polyethylene oxide (300kDa) 10.3829% 37.0480ug solid Natrosol 250M 0.6057% 2.161lug solid Avicel RC-591F 6.9749% 24.8877ug solid Monobasic potassium phosphate (annhydrous) 14.7445% 52.6107ug solid Dibasic potassium phosphate (annhydrous) 19.9006% 71.0087ug solid Disodium Succinate hexahydrate 7.5753% 27.0299ug solid Potassium Hydroxide 4.3289% 15.4462ug solid Quinoprotein glucose dehydrogenase 2.1225% 7.5734ug (EnzC#: 184.108.40.206) solid PQQ 0.0546% 0.1947ug solid Trehalose 24.3328% 86.8243ug solid Mediator BM 31.1144 8.5553% 30.5268ug solid Triton X-100 0.4220% 1.5059ug The method for the manufacture of the glucose biosensor for this Example 4 is the same in all respects as disclosed in U.S. Patent No. 5,997,817 except for the manufacture of the reagent. A protocol for the preparation of the preferred embodiment nitrosoaniline reagent is as follows:
Step 1: Prepare a buffer solution by adding 1.54g of dibasic potassium phosphate (anhydrous) to 43.5 g of deionized water. Mix until the potassium phosphate is dissolved.
Step 2: To the solution from step 1, add 1.14g of monobasic potassium phosphate and mix until dissolved.
Step 3: To the solution from step 2, add 0.59g of disodium succinate (hexahydrate) and mix until dissolved.
Step 4: Verify that the pH of the solution from step 3 is 6.7 +/- 0.1.
Adjustment should not be necessary.
Step 5: Prepare a 5g aliquot of the solution from step 4, and to this add 113 kilounits (by DCIP assay) of the apoenzyme of quinoprotein glucose dehydrogenase (EC#: 220.127.116.11). This is approximately 0.1646g. Mix, slowly, until the protein is dissolved.
Step 6: To the solution from step 5, add 4.2 milligrams of PQQ and mix for no less than 2 hours to allow the PQQ and the apoenzyme to reassociate in order to provide functional enzyme.
Step 7: To the solution from step 4, add 0.66g of the mediator precursor, N,N-bis(hydroxyethyl)-3-methoxy-4-nitrosoaniline (hydrochloride) (BM 31.1144). Mix until dissolved (this solution will have a greenish black coloration).
Step 8: Measure the pH of the solution from step 7 and adjust the pH to a target of 7.0 +/- 0.1. Normally this is accomplished with 1.197g of 5N potassium hydroxide. Because the specific amount of potassium hydroxide may vary as needed to reach the desired pH, generally deviations in mass from the 1. 197g are made up from an aliquot of 3.309g deionized water which is also added at this step.
Step 9: Prepare a solution of Natrosol 250M (available from Aqualon), by slowly sprinkling 0.047g over 44.57g of deionized water which is mixed (using a rotary mixer and blade impeller) at a rate of approximately 600 rpm in a vessel of sufficient depth such that the rotor blades are not exposed nor the solution running over. Mix until the Natrosol is completely dissolved.
Step 10: Prepare a suspension of Avicel RC-591F (available from FMS), by slowly sprinkling 0.54g onto the surface of the solution from step 9, mixing at a rate of approximately 600 rpm for not less than 60 minutes before proceeding.
5 Step 11: To the suspension from step 10, gradually add 0.81 g of Polyethylene oxide of 300kDa mean molecular weight while mixing and continue to mix for not less than 60 minutes before proceeding.
Step 12: Gradually add the solution from step 8 to the suspension from step 11 10 while mixing. Reduce the mixing rate to 400 rpm.
Step 13: To the reagent from step 12, add 1.89g of Trehalose and continue mixing for not less than 15 minutes.
15 Step 14: To the reagent from step 13, add 32.7mg of Triton X-100 (available from Roche Diagnostics) and continue mixing.
Step 15: To the reagent from step 14, add the enzyme solution from step 6. Mix for no less than 30 minutes. At this point the reagent is complete. At room 20 teperature the wet reagent mass is considered acceptable for use for 24 hours.
Spiked venous blood samples were used. Five levels of glucose, four temperatures (19, 23, 32 and 38 C) and five levels of hematocrit (20, 30, 45, and 70%) were independently varied, producing a covariance study with 100 25 samples. 16 test strips 300 were tested for each unique combination of glucose, temperature and hematocrit. The blood samples were applied to test strip 300 and the excitation potentials illustrated in Figure 13 were applied to the electrodes.
The excitation comprised a 3.2 kHz AC signal for approximately 4.0 seconds, a 2.13 kHz AC signal for approximately 0.1 seconds, a 1.07 kHz AC signal for 30 approximately 0.1 seconds, a 200 Hz AC signal for approximately 0.1 seconds, a 25 Hz AC signal for approximately 0.1 seconds, followed by a DC signal of 550 mV for approximately 1.0 second. All four AC signals had an amplitude of 56.56 mV peak. The Total Test Time was 5.5 seconds from sample application time.
In this Example 4, the AC response of the sample was derived as admittance (the inverse of impedance). The admittance response is proportionate to the hematocrit level of the sample in a temperature dependent manner. The relationship between admittance, hematocrit and testing temperature is illustrated in Figure 14. As compared to the test strip architecture of Example 2, the orthogonality of the temperature and hematocrit influence on glucose was not as strong in this Example 4, therefore a cross product term (T x HCT) was added to the admittance regression formula used in Figure 14. The data used for the admittance charted in Figure 14 is the last admittance measurement made for each sample during the 3.2 kHz AC portion of the excitation illustrated in Figure 13.
Regression analysis of this data allows admittance, hematocrit and temperature to be related according to the following formula:
Hest = (Y3.2kHz + CO+ cidT)/(c2 T + C3) (Equation 7) It was determined that the admittance measurement made at 3.2 kHz was best correlated with hematocrit for this test system. Using this relationship to predict the blood hematocrit is accomplished using test temperature data reported by the temperature sensor in the meter and the measured admittance. In Equation 7, co, c1, c2 and c3 are constants, dT is the deviation in temperature from a center defined as "nominal" (24 C for example), and Hest is the estimated deviation in hematocrit from a similar "nominal" value. For the present purposes, the actual hematocrit value is not necessary, and it is generally preferred to produce a response which is proportionate but centers around a nominal hematocrit. Thus, for a 70%
hematocrit, the deviation from a nominal value of 42% would be 28%, while conversely for a 20% hematocrit the deviation from the same nominal value would be -22%.
By using the AC admittance measurement to estimate the hematocrit level using Equation 7, the accuracy of the DC glucose response can be greatly improved by combining the estimated hematocrit, temperature and DC response to correct for the hematocrit interference in the DC response as follows (same as Equation 2 above):
PRED = (ao + hctiHest + hct2Hest2 + tau1dT + tau2dT2) (Equation 8) + (a1DC)(1 + hct3Hest + hct4Hest2)(1 + tau3dT + tau4dT2) The constants in Equation 8 can be determined using regression analysis, as is known in the art.
Figure 15 illustrates the uncompensated 5.5 second DC glucose response of all of the blood samples as hematocrit and temperature vary (ignoring the AC
measurement data). As will be appreciated, there is a wide variation in the DC
current response as temperature and hematocrit vary. Figure 16 illustrates the correlation between the actual blood glucose level of the sample versus the predicted response using Equation 8. As can be seen, when the DC response is compensated for hematocrit levels using the AC response data, an overall r2 value of 0.9818 is achieved with a Total Test Time of 5.5 seconds. This demonstrates the applicability of the present invention in achieving high accuracy and fast test times with a different reagent class than was used in Examples 1-3.
Example 5: Combined AC and DC Measurement Using a 0.397,u1 Sample The measurement methods of the present invention have been found to be useful with other test strip designs as well. Example 5 was conducted using the test strip design illustrated in Figures 17A-B, and indicated generally at 1700.
Referring to Figure 17A, the test strip 1700 comprises a bottom foil layer formed from an opaque piece of 350 m thick polyester (in the preferred embodiment this is Melinex 329 available from DuPont) coated with a 50 nm conductive (gold) layer (by sputtering or vapor deposition, for example).
Electrodes and connecting traces are then patterned in the conductive layer by a laser ablation process to form working, counter, and dose sufficiency electrodes (described in greater detail hereinbelow) as shown. The laser ablation process is performed by means of an excimer laser which passes through a chrome-on-quartz mask. The mask pattern causes parts of the laser field to be reflected while allowing other parts of the field to pass through, creating a pattern on the gold which is ejected from the surface where contacted by the laser light.
Examples of the use of laser ablation techniques in preparing electrodes for biosensors are described in US 2002/0192115 and in US
The bottom foil layer 1702 is then coated in the area extending over the electrodes with a reagent layer 1704 in the form of an extremely thin reagent film.
This procedure places a stripe of approximately 7.2 millimeters width across the bottom foil 1702 in the region labelled "Reagent Layer" on Figure 17. In the present Example, this region is coated at a wet-coat weight of 50 grams per square meter of coated surface area leaving a dried reagent less than 20 m thick.
The reagent stripe is dried conventionally with an in-line drying system where the nominal air temperature is at 110 C. The rate of processing is nominally 30-38 meters per minute and depends upon the rheology of the reagent.
The materials are processed in continuous reels such that the electrode pattern is orthogonal to the length of the reel, in the case of the bottom foil 1702.
Once the bottom foil 1702 has been coated with reagent, the spacer is slit and placed in a reel-to-reel process onto the bottom foil 1702. Two spacers 1706 formed from 100 pm polyester (in the preferred embodiment this is Melinex 329 available from DuPont) coated with 25 m PSA (hydrophobic adhesive) on both the dorsal and ventral surfaces are applied to the bottom foil layer 1702, such that the spacers 1706 are separated by 1.5 mm and the working, counter and dose sufficiency electrodes are centered in this gap. A top foil layer 1708 formed from 100 m polyester coated with a hydrophilic film on its ventral surface (using the process described in U.S. Patent No. 5, 997,817) is placed over the spacers 1706.
In the preferred embodiment, the hydrophilic film is coated with a mixture of Vitel and Rhodapex surfactant at a nominal thickness of 10 microns. The top foil layer 1708 is laminated using a reel-to-reel process. The sensors can then be produced from the resulting reels of material by means of slitting and cutting.
The 1.5 mm gap in the spacers 1706 therefore forms a capillary fill space between the bottom foil layer 1702 and the top foil layer 1708. The hydrophobic adhesive on the spacers 1706 prevents the test sample from flowing into the reagent under the spacers 1706, thereby defining the test chamber volume.
Because the test strip 1700 is 5 mm wide and the combined height of the spacer 1706 and conductive layer is 0.15 mm, the sample receiving chamber volume is 5 mm x 1.5 mm x 0.15 mm = 1.125 l (Equation 9) As shown in Figure 17B, the distance from the sample application port 1710 and the dose sufficiency electrodes is 1.765 mm. The volume of sample needed to sufficiently cover the working, counter and dose sufficiency electrodes (i.e. the minimum sample volume necessary for a measurement) is 1.5 mm x 1.765 mm x 0.15 mm = 0.397 l (Equation 10) The reagent composition for the test strip 1700 is given in Tables V and VI.
Table V: Reagent Mass Composition - Prior to Dispense and Drying Component % w/w Mass for Ikg solid Polyethylene oxide (300kDa) 1.0086% 10.0855g solid Natrosol 250M 0.3495% 3.4954g solid Carboxymethylcellulose 7HF 0.3495% 3.4954g solid Monobasic potassium phosphate (annhydrous) 0.9410% 9.4103g solid Dibasic potassium phosphate (trihydrous) 1.6539% 16.5394g solid Disodium Succinate hexahydrate 0.2852% 2.8516g solid Potassium Hydroxide 0.2335% 2.3351g solid Quinoprotein glucose dehydrogenase 0.3321% 3.3211g (EnzC#: 18.104.22.168) solid PQQ 0.0093% 0.0925g solid Trehalose 0.7721% 7.7210g solid Mediator 31.1144 0.6896% 6.8956g solid Triton X-100 0.0342% 0.3419g solvent Water 93.7329% 937.3293g % Solids 6.6585%
Target pH 7 Specific Enzyme Activity Used (U/mg) 689 DCIP
5 Wet Reagent Coat Weight per Sensor (ug/mm2) 50 Table VI: Reagent Layer Composition - After Drying Component % w/w Mass per Sensor*
solid Polyethylene oxide (300kDa) 15.1469% 3.7821ug solid Natrosol 250M 5.2495% 1.3108ug solid Carboxymethylcellulose 7HF 5.2495% 1.3108ug solid Monobasic potassium phosphate (annhydrous) 14.1328% 3.5289ug solid Dibasic potassium phosphate (trihydrous) 24.8395% 6.2023ug solid Disodium Succinate hexahydrate 4.2827% 1.0694ug solid Potassium Hydroxide 3.5069% 0.8757ug solid Quinoprotein glucose dehydrogenase 4.9878% 1.2454ug (EnzC#: 22.214.171.124) solid PQQ 0.1390% 0.0347ug solid Trehalose 11.5958% 2.8954ug solid Mediator BM31.1144 10.3562% 2.5859ug solid Triton X-100 0.5135% 0.1282ug * "Mass per Sensor" is the amount of the component within the capillary; this does not reflect the reagent that is outside of the capillary.
A protocol for the preparation of the preferred embodiment nitrosoaniline reagent is as follows:
Step 1: Prepare a buffer solution by adding 1.654g of dibasic potassium phosphate (trihydrous) to 31.394 g of deionized water. Mix until the potassium phosphate is dissolved.
Step 2: To the solution from step 1, add 0.941g of monobasic potassium phosphate and mix until dissolved.
Step 3: To the solution from step 2, add 0.285g of disodium succinate (hexahydrate) and mix until dissolved.
Step 4: Verify that the pH of the solution from step 3 is 6.8 +/- 0.1.
Adjustment should not be necessary.
Step 5: Prepare a 4.68g aliquot of the solution from step 4, and to this add kilounits (by DCIP assay) of the apoenzyme of quinoprotein glucose dehydrogenase (EC#: 126.96.36.199). This is approximately 0.3321g. Mix, slowly, until the protein is dissolved.
Step 6: To the solution from step 5, add 9.3 milligrams of PQQ and mix for no less than 2 hours to allow the PQQ and the apoenzyme to reassociate in order to provide functional enzyme.
Step 7: Prepare a solution by dissolving 0.772g of Trehalose into 1.218g of deionized water.
Step 8: After enzyme reassociation, add the solution from step 7 to the solution from step 6 and continue mixing for not less than 30 minutes.
Step 9: To the solution from step 4, add 0.690g of the mediator precursor BM
31.1144. Mix until dissolved (this solution will have a greenish black coloration).
Step 10: Measure the pH of the solution from step 9 and adjust the pH to a target of 7.0 +/- 0.1. Normally this is accomplished with 1.006g of 5N potassium hydroxide. Because the specific amount of potassium hydroxide may vary as needed to reach the desired pH, generally deviations in mass from the 1.006g are made up from an aliquot of 3.767g deionized water which is also added at this step.
Step 11: Prepare a solution of Natrosol 250M (available from Aqualon), by slowly sprinkling 0.350g over 56.191g of deionized water which is mixed (using a rotary mixer and blade impeller) at an initial rate of approximately 600 rpm in a vessel of sufficient depth such that the rotor blades are not exposed nor the solution running over. As the Natrosol dissolves, the mixing rate needs to be increased to a speed of 1.2 - 1.4 krpm. Mix until the Natrosol is completely dissolved. Note that the resulting matrix will be extremely viscous - this is expected.
Step 12: To the solution from step 11, gradually add 0.350g of Sodium-Carboxymethylcellulose 7HF (available from Aqualon). Mix until the polymer is dissolved.
Step 13: To the suspension from step 13, gradually add 1.01g of Polyethylene oxide of 300kDa mean molecular weight while mixing and continue to mix for not less than 60 minutes before proceeding.
Step 14: Gradually add the solution from step 10 to the suspension from step while mixing.
Step 15: To the reagent from step 14, add 34.2mg of Triton X-100 (available from Roche Diagnostics) and continue mixing.
Step 16: To the reagent from step 15, add the enzyme solution from step 8. Mix for no less than 30 minutes. At this point the reagent is complete. At room teperature the wet reagent mass is considered acceptable for use for 24 hours.
The measurement results illustrated in FIG. 18 show the correlation coefficient r2 between the DC current response and the glucose level as the Read Time varies for three combinations of temperature and hematocrit. These results demonstrate that a robust DC response should be anticipated for tests as fast as 1 second. However, those skilled in the art will recognise that there are undesirable variations in the sensor accuracy (correlation) due to the interfering effects of temperature and hematocrit levels, suggesting that the combined AC and DC
measurement method of the present invention should produce more closely correlated results.
Based upon the encouraging results obtained in Figure 18, a further test was designed using the excitation signal of Figure 19 applied to the test strip 1700. The excitation comprised a 10 kHz AC signal applied for approximately 1.8 seconds, a 20 kHz AC signal applied for approximately 0.2 seconds, a 2 Hz AC signal applied for approximately 0.2 seconds, a 1Hz AC signal applied for approximately 0.2 seconds, and a DC signal applied for approximately 0.5 seconds. The AC signals had an amplitude of 12.7 mV peak, while the DC signal had an amplitude of 550 mV. The Total Test Time was 3.0 seconds.
A covariance study using spiked venous blood samples representing five glucose levels (40, 120, 200, 400 and 600), five hematocrit levels (20, 30, 45, 60 and 70%) and five temperatures (12, 18, 24, 32 and 44 C) was designed, resulting in 125 separate combinations. As in the previous examples, the relationship between admittance, temperature and hematocrit was examined and plotted (Figure 20 shows the admittance at 20 kHz versus hematocrit as temperature varies) and it was confirmed that the admittance was linearly related to hematocrit in a temperature dependent manner. An additional discovery, however, was that the phase angle of the AC response was correlated with hematocrit in a temperature independent manner. The phase angle of the 20 kHz AC response is plotted versus hematocrit in Figure 21. The results for phase angle measured at 10 kHz are similar. The hematocrit of the blood sample may therefore be reliably estimated using only the phase angle information as follows:
Hest = co + c1((D1okHz - (D20kHz) + C2(c2kHz - (D1kxz) (Equation 11) For the test strip used in this Example 5, the correlation between phase angle and hematocrit was better at higher frequencies. Because of this, the c2 constant approaches zero and Hest can reliably be estimated using only the 10 kHz and 20 kHz data. Use of lower frequencies, however, allows for slight improvements in the strip-to-strip variability of the H,st function. The present invention therefore may be used to estimate hematocrit using only AC phase angle measurements preferably made at at least one AC frequency, more preferably made at at least two AC frequencies, and most preferably made at at least four AC
Because the hematocrit can be determined using only the AC response data, and we know from Figure 20 that admittance is linearly related to hematocrit and temperature, we can now determine the temperature of the sample under analysis using only the AC response as follows:
Test = bo + b1(Y1okHz - Y2okH,) + b2(Y2kHz - Y1kHz) + b3Hest (Equation 12) where bo, b1, b2 and b3 are constants. It will be appreciated that the estimation of hematocrit and temperature from the AC response data may be made with more or fewer frequency measurements, and at different frequencies than those chosen for this example. The particular frequencies that produce the most robust results will be determined by test strip geometries and dimensions. The present invention therefore may be used to estimate test sample temperature using only AC
response measurements preferably made at at least one AC frequency, more preferably made at at least two AC frequencies, and most preferably made at at least four AC
5 Those skilled in the art will recognise that the direct measurement of the temperature of the sample under test (by means of the AC response) is a great improvement over prior art methods for estimating the temperature of the sample.
Typically, a thermistor is placed in the test meter near where the test strip is inserted into the meter. Because the thermistor is measuring a temperature remote 10 from the actual sample, it is at best only a rough approximation of the true sample temperature. Furthermore, if the sample temperature is changing (for example due to evaporation), then the thermal inertia of the test meter and even the thermistor itself will prevent the meter-mounted thermistor from accurately reflecting the true temperature of the sample under test. By contrast, the temperature estimation of 15 the present invention is derived from measurements made within the sample under test (i.e. within the reaction zone in which the sample under test reacts with the reagent), thereby eliminating any error introduced by the sample being remote from the measuring location. Additionally, the temperature estimation of the present invention is made using data that was collected very close in time to the 20 glucose measurement data that will be corrected using the temperature estimation, thereby further improving accuracy. This represents a significant improvement over the prior art methods.
As a demonstration of the effectiveness of the method of this Example 5 for correcting for the effects of interferants on the blood glucose measurement, the 25 uncompensated DC current response versus known glucose concentration is plotted in Figure 22 for all 125 combinations of glucose, temperature and hematocrit (the AC measurements were ignored when plotting this data). As will be appreciated by those skilled in the art, the data exhibits huge variation with respect to hematocrit and temperature.
30 As previously discussed, the accuracy of the DC glucose response can be greatly improved by combining the estimated hematocrit, temperature and DC
response to correct for the hematocrit and temperature interference in the DC
response as follows:
PRED = (ao + hctiHest + hct2Hest2 + taulTest + taut Test) (Equation 13) + (a1DC)(1 + hct3Hest + hct4Hest2)(1 + tau3Test + tau4Test) The constants in Equation 13 can be determined using regression analysis, as is known in the art. The present invention therefore allows one to estimate hematocrit by using the AC phase angle response (Equation 11). The estimated hematocrit and the measured AC admittance can be used to determine the estimated temperature (Equation 12). Finally, the estimated hematocrit and estimated temperature can be used with the measured DC response to obtain the predicted glucose concentration (Equation 13).
Applying the above methodology to the test data plotted in Figure 22, we obtain the predicted glucose versus DC current response illustrated in Figure 23.
This data represents 125 covariant samples having hematocrit levels ranging from 20%- 70% and temperatures ranging from 12 C - 44 C. Even with these wide variations in interferant levels, the measurement method of the present invention produced an overall r2 correlation of 0.9874 using a 3.0 second Total Test Time.
Example 6: Simultaneous AC and DC Measurement Using a 0.397, I Sample Using the same test strip 1700 and reagent described above for Example 5, the excitation profile illustrated in Figure 24 was utilized in order to decrease the Total Test Time. As described above with respect to Example 5, it was determined that the phase angle at 20 kHz and at 10 kHz were most closely correlated with the hematocrit estimation. It was therefore decided to limit the AC portion of the excitation to these two frequencies in Example 6 in order to decrease the Total Test Time. In order to make further reductions in Total Test Time, the 10 kHz AC
excitation was applied simultaneously with the DC signal (i.e. an AC signal with a DC offset), the theory being that this combined mode would allow for the collection of simultaneous results for DC current, AC phase and AC admittance, providing the fastest possible results. Therefore, the 20 kHz signal was applied for 0.9 seconds. Thereafter, the 10 kHz and DC signals were applied simultaneously for 1.0 second after a 0.1 second interval.
For this Example 6, 49 spiked venous blood samples representing seven glucose levels and seven hematocrit levels were tested. The correlation coefficient r2 between the DC current and the blood hematocrit was then examined at three DC measurement times: 1.1 seconds, 1.5 seconds and 1.9 seconds after sample application. These correlations are plotted versus hematocrit level in Figure 25.
All of these results are comparable, although the correlation is generally poorest at 1.1 seconds and generally best at 1.5 seconds. The minimum correlation coefficient, however, exceeds 0.99.
Figure 26 illustrates the phase angle at 20 kHz plotted against hematocrit levels. The correlation between these two sets of data is very good, therefore it was decided that the 10 kHz data was unnecessary for estimating hematocrit.
The hematocrit can therefore be estimated solely from the 20 kHz phase angle data as follows:
Hest = co + C1(D2okHz (Equation 14) Figure 27 illustrates the DC current response versus glucose level for all measured hematocrit levels as the read time is varied between 1.1 seconds, 1.5 seconds and 1.9 seconds. Not surprisingly, the DC current at 1.1 seconds is greater than the DC current at 1.5 seconds, which is greater than the DC current at 1.9 seconds. Those skilled in the art will recognise that the hematocrit level has a large effect on the DC current, particularly at high glucose concentrations.
As discussed hereinabove, the accuracy of the DC glucose response can be greatly improved by compensating for the interference caused by hematocrit as follows:
PRED = (ao + hctiHest + hct2Hest2) + (a1DC)(1 + hct3Hest + hcti.Hest2) (Equation 15) Note that Equation 15 does not include temperature compensation terms since temperature variation was not included in the experiment of this Example 6, it can be reasonably inferred from previous examples that a Test term could be included using the 10 kHz and 20 kHz admittance values in combination with the Hest term.
Because the hematocrit can be reliably estimated using only the 20 kHz phase angle measurement data, the hematocrit compensated predicted glucose response can be determined using only this phase angle information and the measured DC
response. The compensated DC response versus glucose level for only the DC
read at 1.1 seconds (representing a 1.1 second Total Test Time) is illustrated in Figure 28. The data shows an overall r2 correlation of 0.9947 with a 1.1 second Total Test Time.
The same data for the 1.5 second DC read is illustrated in Figure 29, showing an overall r2 correlation of 0.9932 for a 1.5 second Total Test Time.
The same data for the 1.9 second DC read is illustrated in Figure 30, showing an overall r2 correlation of 0.9922 for a 1.9 second Total Test Time. Surprisingly, the r2 correlation actually decreased slightly with the longer test times.
Notwithstanding this, the correlation coefficients for all three compensated data sets - where all?
hematocrits ranging from 20% through 60% are combined - were in excess of 0.99, demonstrating the applicability of the present invention to yield a blood glucose test as fast as 1.1 seconds, combined with improved accuracy, where the sensor requires less than 0.4 microliters of blood in order to perform the glucose measurement test.
Example 7: Use of AC Phase Angle to Detect an Abused Sensor In order to provide an extra measure of quality control to the analyte measurement process, particularly when the test system is to be used by a non-professional end user, it is desirable to detect sensors (test strips) that have been mis-dosed (double dosed, etc.), that have been previously used, or that have degraded enzymes (from being stored in too humid an environment, being too old, etc.). These conditions are collectively referred to as "abused sensors." It is desired to devise a test that will abort the analyte measurement process (or at least warn the user that the test results may not be accurate) if an abused sensor is inserted into the test meter.
When performing a blood glucose analysis, the test meter will typically make several successive current measurements as the blood sample continues to react with the reagent chemistry. As is well known in the art, this response current is known as the Cottrell current and it follows a pattern of decay as the reaction progresses. We may define a Cottrell Failsafe Ratio (CFR) as follows:
The Cottrell response of the biosensor in the Confidence system can be given by:
Ico eõ = nFA,[D Ct (Equation 16) where: n = electrons freed per glucose molecule F = Faraday's Constant A = Working electrode surface area t = elapsed time since application of excitation D = diffusion coefficient C = glucose concentration a = a cofactor-dependent constant.
All of the parameters of this equation will normally be constant for the sensor except the glucose concentration and time. We can therefore define a normalized Cottrell failsafe ratio(NCFR) as:
m m nFA1D m Elk Ctk Etk NCFR = k=1 = k=1 = k 1 = Constant (Equation 17) mIm in nFA/D Ct mtm M
As the time terms in this equation are known and constant for a sensor measurement, the ratio always yields a constant for Cottrell curves with identical sample times and intervals. Therefore, the sum of sensor currents divided by the last sensor current should yield a constant independent of glucose concentration.
This relationship is used in the preferred embodiment to detect potentially faulty biosensor responses.
A Current Sum Failsafe can be devised that places a check on the Cottrell 5 response of the sensor by summing all of the acquired currents during sensor measurement. When the final current is acquired, it is multiplied by two constants (which may be loaded into the meter at the time of manufacture or, more preferably, supplied to the meter with each lot of sensors, such as by a separate code key or by information coded onto the sensor itself). These constants represent 10 the upper and lower threshold for allowable NCFR values.
The two products of the constants multiplied by the final current are compared to the sum of the biosensor currents. The sum of the currents should fall between the two products, thereby indicating that the ratio above was fulfilled, plus or minus a tolerance.
Therefore, the preferred embodiment performs the following check when there is a single DC block:
(Ir)(C1) 5 Ik 5 (Ia)(CU) (Equation 18) k=1 where Cu = upper constant from the Code Key C1= lower constant from the Code Key Im = final biosensor current Because some embodiments may contain two DC blocks in the measurement sequence, a Modified Cottrell Failsafe Ratio (MCFR) can be formulated as:
MCFR = w1NCFR1 + w2NCFR2 (Equation 19) w1+W2 where w1, w2 = weighting constants (e.g. from the Code Key) NCFR1, NCFR2 = the Normalized Cottrell Failsafe Ratios for DC blocks 1 and 2 respectively.
Therefore, the preferred embodiment performs the following check when there are two DC blocks:
m1 /n2 (w1 + W2)Im1I/n2CL < (Wllm2 Y Ik + W2Im1 EIk) :!~(W1 + W2)I,nllm2Cu (Equation 20) k=1 k=1 where Cu = upper constant from the Code Key CL = lower constant from the Code Key Iml, 1.2 = final biosensor current in DC blocks 1 and 2 The NCFR (and MCFR) is correlated with hematocrit. As demonstrated hereinabove in Example 3, the AC phase angle is also correlated with hematocrit.
It follows then, that the AC phase angle and the NCFR are correlated with one another. This relationship holds only if the sensor is unabused. The correlation degrades for an abused sensor.
It is therefore possible to design an equation to analyze the measured phase angle data to produce a failsafe calculation that will indicate if an abused sensor is being used. In the preferred embodiment, it was chosen to use the difference between the phase angles measured at two separate frequencies in order to make the test more robust to errors caused by parasitic resistance, etc. Applying the arctangent function to drive the two populations to different asymptotes yields the following failsafe equation:
FAILSAFE = 1000 x arctan[NCFR/(fso + fsl('lokHZ - (D20kHz))] (Equation 21) where 1000 = scaling factor NCFR = Cottrell Failsafe Ratio fso = linear regression intercept fsl = linear regression slope I)iokxz = phase angle at 10 kHz 02okH, = phase angle at 20 kHz Using Equation 21, the intercept term fso can be chosen such that a FAILSAFE value below zero indicates an abused sensor, while a FAILSAFE value above zero indicates a non-abused sensor. Those skilled in the art will recognise that the opposite result could be obtained by choosing a different intercept.
Use of Dose Sufficiency Electrodes As described hereinabove, it has been recognised that accurate sample measurement requires adequate coverage of the measurement electrodes by the sample. Various methods have been used to detect the insufficiency of the sample volume in the prior art. For example, the Accu-Chek Advantage glucose test meter sold by Roche Diagnostics Corporation of Indianapolis, Indiana warned the user of the possible inadequacy of the sample volume if non-Cotrellian current decay was detected by the single pair of measurement electrodes. Users were prompted to re-dose the test strip within a specified time allotment.
The possibility of insufficient sample size has been heightened in recent years due to the use of capillary fill devices used in conjunction with blood lancing devices designed to minimize pain through the requirement of only extremely small sample volumes. If an inadequate amount of sample is drawn into the capillary fill space, then there is a possibility that the measurement electrodes will not be adequately covered and the measurement accuracy will be compromised. In order to overcome the problems associated with insufficient samples, various prior art solutions have been proposed, such as placing an additional electrode downstream from the measurement electrodes; or a single counter electrode having a sub-element downstream and major element upstream of a working electrode; or an indicator electrode arranged both upstream and downstream from a measurement electrode (allowing one to follow the flow progression of the sample across the working and counter electrodes or the arrival of the sample at a distance downstream). The problem associated with each of these solutions is that they each incorporate one or the other electrode of the measurement pair in communication with either the upstream or the downstream indicator electrodes to assess the presence of a sufficient volume of sample to avoid biased test results.
Despite these prior art design solutions, failure modes persist wherein the devices remain prone to misinterpretation of sample sufficiency. The present inventors have determined that such erroneous conclusions are related primarily to the distances between a downstream member of a measurement electrode pair (co-planar or opposing geometries) and the dose detection electrode, in combination with the diversity of non-uniform flow fronts. A sample traversing the capillary fill space having an aberrant (uneven) flow front can close the circuit between a measurement electrode and an indicator electrode and erroneously advise the system that sufficient sample is present to avoid a biased measurement result.
Many factors employed in the composition and/or fabrication of the test strip capillary fill spaces influence such irregular flow front behavior.
These factors include:
= disparities between surface energies of different walls forming the capillary fill space.
= contamination of materials or finished goods in the test strip manufacturing facility.
= unintentional introduction of a contaminant from a single component making up the walls of the capillary fill space (an example being a release agent (typically silicon) that is common to manufacturing processes wherein release liners are used).
= hydrophobic properties of adhesives (or contaminated adhesives) used in the lamination processes.
= disparate surface roughnesses on the walls of the capillary fill space.
= dimensional aspect ratios.
= contaminated mesh materials within the capillary fill space.
= non-homogeneous application of surfactants onto mesh materials within the capillary fill space.
Another problem with prior art dose sufficiency methodologies determined by the present inventors relates to the use of one or the other of the available measurement electrodes in electrical communication with an upstream or downstream dose detection electrode. In such arrangements, the stoichiometry of the measurement zone (the area above or between the measurement electrodes) is perturbed during the dose detect/dose sufficiency test cycle prior to making a measurement of the analyte of interest residing in the measurement zone. As sample matrices vary radically in make-up, the fill properties of these samples also vary, resulting in timing differences between sample types. Such erratic timing routines act as an additional source of imprecision and expanded total system error metrics.
Trying to solve one or more of these obstacles typically can lead to 1) more complex manufacturing processes (additional process steps each bringing an additional propensity for contamination); 2) additional raw material quality control procedures; 3) more costly raw materials such as laminate composites having mixtures of hydrophobic and hydrophyllic resins and negatively impacting manufacturing costs; and 4) labor-intensive surfactant coatings of meshes and or capillary walls.
Example 8: Detennination of Fluid Flow Front Behavior in a Capillary Fill Space In order to design an electrode system that will adequately indicate dose sufficiency in a test strip employing a capillary fill space, an experiment was performed to examine the flow front shape at the leading edge of the sample as it progresses through the capillary fill space. Test fixtures comprising two sheets of clear polycarbonate sheets joined together with double-sided adhesive tape were used, where the capillary fill space was formed by cutting a channel in the double-sided tape. Use of the polycarbonate upper and lower sheets allowed the flow fronts of the sample to be videotaped as it flowed through the capillary fill space.
Specifically, the test devices were laminated using laser cut 1mm thick Lexan polycarbonate sheets (obtained from Cadillac Plastics Ltd., Westlea, Swindon SN5 7EX, United Kingdom). The top and bottom polycarbonate sheets 5 were coupled together using double-sided adhesive tapes (#200MP High Performance acrylic adhesive obtained from 3M Corporation, St. Paul, MN). The capillary channels were defined by laser cutting the required width openings into the double-sided tape. Tape thicknesses of 0.05 m, 0.125 m, and 0.225 m were used to give the required channel heights. The dimensions of the capillary spaces 10 of the test devices are tabulated in FIG. 31.
The top and bottom polycarbonate parts were laminated together with the laser cut adhesive tapes using a custom-built jig to ensure reproducible fabrication.
For each test device, a fluid receptor region defineing the entrance to the capillary channel was formed by an opening pre-cut into the upper polycarbonate sheet and 15 adhesive tape components. For each of the three channel heights, channel widths of 0.5mm, 1.00mm, 1.5mm, 2.00mm, 3.00mm, and 4.00mm were fabricated. The capillary channel length for all devices was 50mm. Twenty-eight (28) of each of the eighteen (18) device types were constructed. The assembled devices were plasma treated by Weidman Plastics Technology of Dortmund, Germany. The 20 following plasma treatment conditions were used:
Processor: Microwave plasma processor 400 Microwave Power: 600W
Gas: 02 25 Pressure: 0.39 miilibar Gas Flow: 150 ml/min Time: 10 minutes Surface Energy Pre-Treatment: <38 mN/m Surface Energy Post-Treatment: 72 mN/m The plasma-treated devices were stored at 2 - 8 C when not in use. The devices were allowed to equilibrate to room temperature for one (1) hour minimum before use.
Each of the test devices was dosed with a fixed volume of venous blood having a hematocrit value of 45%. Flow and flow front behavior was captured on videotape for later analysis. It was determined that the relative dimensions of the capillary fill channel determined the flow front behavior. Devices to the left of the dashed line in FIG. 31 (devices A2, A4, B2, B4, B5, C2, C4, and C5) resulted in a convex flow front behavior, while devices to the right of the dashed line (devices A6, A8, All, B6, B8, B11, C6, C8, and C11) displayed a concave flow front behavior. Both the convex and concave flow front behaviors are schematically illustrated in FIG. 31. This data shows that the aspect ratio between the height and the width of the capillary fill space is a determining factor in whether the sample flow front is convex or concave.
Use of Dose Sufficiency Electrodes cont'd The problems associated with a concave flow front in a capillary fill space are illustrated in FIGs. 32A-C. In each of the figures, the test strip includes a working electrode 3200, a reference electrode 3202, and a downstream dose sufficiency electrode 3204 that works in conjunction with one of the measurement electrodes 3200 or 3202. In addition to the measurement zone stoichiometry problems associated with the use of the dose sufficiency electrode 3204 in conjunction with one of the measurement electrodes discussed above, FIGs. 32A-C
illustrate that a sample flow front exhibiting a concave shape can also cause biased measurement results. In each drawing, the direction of sample travel is shown by the arrow. In FIG. 32A, the portions of the sample adjacent to the capillary walls have reached the dose sufficiency electrode 3204, thereby electrically completing the DC circuit between this electrode and one of the measurement electrode pair that is being monitored by the test meter in order to make the dose sufficiency determination. Although the test meter will conclude that there is sufficient sample to make a measurement at this time, the sample clearly has barely reached the reference electrode 3202 and any measurement results obtained at this time will be highly biased.
Similarly, FIG. 32B illustrates the situation where the dose sufficiency electrode 3204 has been contacted (indicating that the measurement should be started), but the reference electrode 3202 is only partially covered by the sample.
Although the sample has reached the reference electrode 3202 at this time, the reference electrode 3202 is not completely covered by sample, therefore any measurement results obtained at this time will be partially biased. Both of the situations illustrated in FIGs. 32A-B will therefore indicate a false positive for dose sufficiency, thereby biasing the measurement test results. Only in the situation illustrated in FIG. 32C, where the reference electrode 3202 is completely covered by the sample, will the measurement results be unbiased due to the extent of capillary fill in the measurement zone.
The present invention solves the stoichiometric problems associated with the prior art designs pairing the dose sufficiency electrode with one of the measurement electrodes when making the dose sufficiency determination. As shown in FIG. 33, the present invention comprehends a test strip having an independent pair of dose sufficiency electrodes positioned downstream from the measurement electrodes. The test strip is indicated generally as 3300, and includes a measurement electrode pair consisting of a counter electrode 3302 and a working electrode 3304. The electrodes may be formed upon any suitable substrate in a multilayer test strip configuration as is known in the art and described hereinabove.
The multilayer configuration of the test strip provides for the formation of a capillary fill space 3306, also as known in the art. Within the capillary fill space 3306, and downstream (relative to the direction of sample flow) from the measurement electrodes 3302 and 3304 are formed a dose sufficiency working electrode 3308 and a dose sufficiency counter electrode 3310, together forming a dose sufficiency electrode pair.
When the test strip 3300 is inserted into the test meter, the test meter will continuously check for a conduction path between the dose sufficiency electrodes 3308 and 3310 in order to determine when the sample has migrated to this region of the capillary fill space. Once the sample has reached this level, the test meter may be programmed to conclude that the measurement electrodes are covered with sample and the sample measurement sequence may be begun. It will be appreciated that, unlike as required with prior art designs, no voltage or current need be applied to either of the measurement electrodes 3302 and 3304 during the dose sufficiency test using the test strip design of FIG. 33. Thus the stoichiometry of the measurement zone is not perturbed during the dose sufficiency test cycle prior to making a measurement of the analyte of interest residing in the measurement zone. This represents a significant improvement over the dose sufficiency test methodologies of the prior art.
The test strip 3300 is also desirable for judging dose sufficiency when the capillary fill space is designed to produce samples that exhibit a convex flow front while filling the capillary fill space 3306, as illustrated in FIG. 34A. As can be seen, the measurement zone above the measurement electrodes 3302 and 3304 is covered with sample when the convex flow front reaches the dose sufficiency electrode pair 3308,3310. The test strip design 3300 may not, however, produce ideal results if the capillary fill space 3306 allows the sample to exhibit a concave flow front while filling, as shown in FIG. 34B. As can be seen, the peripheral edges of the concave flow front reach the dose sufficiency electrodes 3308,3310 before the measurement zone has been completely covered with sample. With DC
or low frequency excitation (discussed in greater detail hereinbelow), the dose sufficiency electrodes 3308,3310 will indicate sample sufficiency as soon as they are both touched by the edges of the flow front. Therefore, the dose sufficiency electrode design shown in the test strip of FIG. 33 works best when the sample filling the capillary space 3306 exhibits a convex flow front. Furthermore, multiple pairs of dose sufficiency electrodes may be provided, each at a different distance from the measurement zone, such that the capability to assess the extent of capillary space 3306 filling may be provided by examining which of the multiple pairs of dose sufficiency electrodes has been bridged by the sample.
It will be appreciated that the dose sufficiency electrodes 3308,3310 have their longest axis within the capillary fill space 3306 oriented perpendicular to the longitudinal axis of the capillary fill space 3306. Such electrodes are referred to herein as "perpendicular dose sufficiency electrodes." An alternative dose sufficiency electrode arrangement is illustrated in FIGs. 35A-B. As shown in FIG.
35A, the present invention also comprehends a test strip having an independent pair of dose sufficiency electrodes positioned downstream from the measurement electrodes, where the dose sufficiency electrodes have their longest axis within the capillary fill space oriented parallel to the longitudinal axis of the capillary fill space. Such electrodes are referred to herein as "parallel dose sufficiency electrodes." The test strip in FIG. 35 is indicated generally as 3500, and includes a measurement electrode pair consisting of a counter electrode 3502 and a working electrode 3504. The electrodes may be formed upon any suitable substrate in a multilayer test strip configuration as is known in the art and described hereinabove.
The multilayer configuration of the test strip provides for the formation of a capillary fill space 3506, also as known in the art. Within the capillary fill space 3506, and downstream (relative to the direction of sample flow) from the measurement electrodes 3502 and 3504 are formed a dose sufficiency working electrode 3508 and a dose sufficiency counter electrode 3510, together forming a parallel dose sufficiency electrode pair.
When the test strip 3500 is inserted into the test meter, the test meter will continuously check for a conduction path between the dose sufficiency electrodes 3508 and 3510 in order to determine when the sample has migrated to this region of the capillary fill space. Once the sample has reached this level, the test meter may be programmed to conclude that the measurement electrodes are covered with sample and the sample measurement sequence may be begun. It will be appreciated that, as with the test strip 3300 (and unlike as required with prior art designs), no voltage or current need be applied to either of the measurement electrodes 3502 and 3504 during the dose sufficiency test using the test strip design of FIG. 35. Thus the stoichiometry of the measurement zone is not perturbed during the dose sufficiency test cycle prior to making a measurement of the analyte of interest residing in the measurement zone. This represents a significant improvement over the dose sufficiency test methodologies of the prior art.
A further improved operation is realized with the parallel dose sufficiency electrodes of the test strip 3500 when the dose sufficiency electrodes are energized with a relatively high frequency AC excitation signal. When a relatively high frequency AC signal is used as the dose sufficiency excitation signal, the dose sufficiency electrodes 3508,3510 display significant edge effects, wherein the excitation signal traverses the gap between the electrodes only when the electrode edges along the gap are covered with the sample fluid. The test strip 3500 is 5 illustrated in enlarged size in FIG. 36 (with only the electrode portions lying within the capillary fill space 3506 and the strip-to-meter electrode contact pads visible).
When one of the pair of dose sufficiency electrodes 3508,3510 is excited with an AC signal, the majority of the signal travels from one electrode edge to the edge of the other electrode (when the edges are covered with sample), rather than from the 10 upper flat surface of one electrode to the upper flat surface of the other electrode.
These paths of edge-to-edge electrical communication are illustrated schematically as the electric field lines 3602 in FIG. 36.
Higher AC frequencies produce the best edge-only sensitivity from the dose sufficiency electrodes. In the preferred embodiment, a 9 mV (+/- 12.7 mV
15 peak-to-peak) excitation signal of 10kHz is used to excite one of the dose sufficiency electrodes. The gap width GW between the edges of the dose sufficiency electrodes 3508,3510 is preferably 100-300 gm, more preferably 150-260 gm, and most preferably 255 gm. A smaller gap width GW increases the amount of signal transmitted between dose sufficiency electrodes whose edges are 20 at least partially covered by sample; however, the capacitance of the signal transmission path increases with decreasing gap width GW.
An advantage of the parallel dose sufficiency electrode design of FIGs. 35 and 36, when used with AC excitation, is that there is substantially no electrical communication between the electrodes until the sample covers at least a portion of 25 the edges along the electrode gap. Therefore, a sample exhibiting the concave flow front of FIG. 35A, where the illustrated sample is touching both of the dose sufficiency electrodes 3508,3510 but is not touching the electrode edges along the gap, will not produce any significant electrical communication between the dose sufficiency electrodes. The test meter will therefore not form a conclusion of dose 30 sufficiency until the sample has actually bridged the dose sufficiency electrodes between the electrode edges along the gap. This will happen only after the rear-most portion of the concave flow front has reached the dose sufficiency electrodes 3508,3510, at which point the sample has completely covered the measurement zone over the measurement electrodes. As can be seen in FIG. 35B, convex sample flow fronts will activate the dose sufficiency electrodes 3508,3510 as soon as the flow front reaches the dose sufficiency electrodes (at which point the sample has completely covered the measurement zone over the measurement electrodes).
Another advantage to the parallel dose sufficiency electrodes illustrated in FIGs. 35 and 36 is that the amount of signal transmitted between the electrodes is proportional to the amount of the gap edges that is covered by the sample. By employing an appropriate threshold value in the test meter, a conclusion of dose sufficiency can therefore be withheld until the sample has covered a predetermined portion of the dose sufficiency electrode gap edge. Furthermore, an analysis of the dose sufficiency signal will allow the test meter to record the percentage of fill of the capillary fill space for each measurement made by the test meter, if desired.
While the electrode geometry itself demonstrates an advantage over previous embodiments in terms of detecting an adequate sample, particularly in the case of a convex flow front, it was found that further improvement is achieved in the use of AC responses over DC responses for sample detection. DC responses have the problems of being sensitive to variations in, for example, temperature, hematocrit and the analyte (glucose for example). AC responses at sufficiently high frequency can be made robust to the variation in the analyte concentration.
Further, the AC response generated at sufficiently high frequencies in such capillary fill devices is primarily limited by the amount of the parallel gap between the electrode edges which is filled by the sample. Thus, for a convex flow front, little or no AC response (in this case admittance) is perceived until the trough of the flow front actually intrudes within the parallel edges of the sample sufficiency electrodes. Further, by means of threshold calibration, the sensor can be made more or less sensitive as is deemed advantageous, with a higher threshold for admittance requiring more of the parallel gap to be filled before test initiation.
A further limitation of existing devices is the inability of the electrode geometry to discern the amount of time needed to fill the capillary space of the sensor. This limitation is caused by having interdependence of the dose sufficiency electrode and the measurement electrodes. This is a further advantage of independent dose sufficiency electrodes. In the preferred embodiment a signal is first applied across the measurement electrodes prior to dosing. When a response is observed, the potential is immediately switched off and a second signal is applied across the dose sufficiency electrodes during which time the system both looks for a response to the signal (indicating electrode coverage) and marks the duration between the first event (when a response is observed at the measurement electrodes) and the second event (when a response is observed at the dose sufficiency electrodes). In cases where very long intervals may lead to erroneous results, it is possible to establish a threshold within which acceptable results may be obtained and outside of which a failsafe is triggered, preventing a response or at a minimum warning the user of potential inaccuracy. The amount of time lag between dosing and detection of a sufficient sample that is considered allowable is dependent upon the particular sensor design and chemistry. Alternatively, an independent pair of dose detection electrodes (not shown) may be added upstream from the measurement electrodes in order to detect when the sample is first applied to the sensor.
While a DC signal could be used for detection in either or both of the above events, the preferred embodiment uses an AC signal at sufficiently high frequency to avoid unnecessarily perturbing the electrochemical response at the measurement electrodes and to provide robust detection with respect to flow front irregularities.
All publications, prior applications, and other documents cited herein are hereby incorporated by reference in their entirety as if each had been individually incorporated by reference and fully set forth.
While the invention has been illustrated and described in detail in the drawings and foregoing description, the description is to be considered as illustrative and not restrictive in character. Only the preferred embodiment, and certain other embodiments deemed helpful in further explaining how to make or use the preferred embodiment, have been shown. All changes and modifications that come within the spirit of the invention are desired to be protected.
providing a biological fluid test strip comprising a fluid flow intake opening, a fluid flow terminus, a capillary fill chamber extending a length along the test strip from the opening to the terminus, a measurement zone positioned in the fill chamber intermediate the opening and the terminus, and at least two dose sufficiency electrodes having a gap therebetween and positioned intermediate the measurement zone and the terminus;
introducing the biological fluid to the opening effective to cause the fluid to flow toward the terminus;
applying a test signal having an AC component to one of the dose sufficiency electrodes;
detecting a response or an absence of the response to the test signal at the other of the dose sufficiency electrodes; and determining a dosage fill property of the test strip.
applying a test signal to one electrode of the second pair of dose sufficiency electrode pairs;
measuring a response to the test signal at the other electrode of the second dose sufficiency electrodes; and determining the dosage fill level based upon the response to both pairs of dose sufficiency electrodes.
applying a test signal to one of the dose detect electrodes; and measuring a first response to the test signal at the other of the dose detect electrodes, the determining being a determining of the time for the biological fluid to fill the chamber based at least in part upon the first response and the second response.
component to one of the dose detect electrodes.
Priority Applications (5)
|Application Number||Priority Date||Filing Date||Title|
|US10687958 US7452457B2 (en)||2003-06-20||2003-10-17||System and method for analyte measurement using dose sufficiency electrodes|
|PCT/US2004/019721 WO2005008231A1 (en)||2003-06-20||2004-06-18||System and method for analyte measurement of biological fluids using dose sufficiency electrodes|
Applications Claiming Priority (1)
|Application Number||Priority Date||Filing Date||Title|
|CA 2714309 CA2714309C (en)||2003-06-20||2004-06-18||System and method for analyte measurement using dose sufficiency electrodes|
|Publication Number||Publication Date|
|CA2530052A1 true CA2530052A1 (en)||2005-01-27|
|CA2530052C true CA2530052C (en)||2010-11-30|
Family Applications (3)
|Application Number||Title||Priority Date||Filing Date|
|CA 2814802 Active CA2814802C (en)||2003-06-20||2004-06-18||System and method for analyte measurement using dose sufficiency electrodes|
|CA 2530052 Active CA2530052C (en)||2003-06-20||2004-06-18||System and method for analyte measurement using dose sufficiency electrodes|
|CA 2714309 Active CA2714309C (en)||2003-06-20||2004-06-18||System and method for analyte measurement using dose sufficiency electrodes|
Family Applications Before (1)
|Application Number||Title||Priority Date||Filing Date|
|CA 2814802 Active CA2814802C (en)||2003-06-20||2004-06-18||System and method for analyte measurement using dose sufficiency electrodes|
Family Applications After (1)
|Application Number||Title||Priority Date||Filing Date|
|CA 2714309 Active CA2714309C (en)||2003-06-20||2004-06-18||System and method for analyte measurement using dose sufficiency electrodes|
Country Status (5)
|US (2)||US7452457B2 (en)|
|JP (1)||JP4681546B2 (en)|
|CA (3)||CA2814802C (en)|
|EP (1)||EP1639355A1 (en)|
|WO (1)||WO2005008231A1 (en)|
Families Citing this family (122)
|Publication number||Priority date||Publication date||Assignee||Title|
|US6036924A (en)||1997-12-04||2000-03-14||Hewlett-Packard Company||Cassette of lancet cartridges for sampling blood|
|US8148164B2 (en)||2003-06-20||2012-04-03||Roche Diagnostics Operations, Inc.||System and method for determining the concentration of an analyte in a sample fluid|
|US20070264721A1 (en) *||2003-10-17||2007-11-15||Buck Harvey B||System and method for analyte measurement using a nonlinear sample response|
|US6391005B1 (en)||1998-03-30||2002-05-21||Agilent Technologies, Inc.||Apparatus and method for penetration with shaft having a sensor for sensing penetration depth|
|US8641644B2 (en)||2000-11-21||2014-02-04||Sanofi-Aventis Deutschland Gmbh||Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means|
|US7892183B2 (en)||2002-04-19||2011-02-22||Pelikan Technologies, Inc.||Method and apparatus for body fluid sampling and analyte sensing|
|US8372016B2 (en)||2002-04-19||2013-02-12||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for body fluid sampling and analyte sensing|
|US8579831B2 (en)||2002-04-19||2013-11-12||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for penetrating tissue|
|US9795334B2 (en)||2002-04-19||2017-10-24||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for penetrating tissue|
|US7229458B2 (en)||2002-04-19||2007-06-12||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7316700B2 (en)||2001-06-12||2008-01-08||Pelikan Technologies, Inc.||Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties|
|US9226699B2 (en)||2002-04-19||2016-01-05||Sanofi-Aventis Deutschland Gmbh||Body fluid sampling module with a continuous compression tissue interface surface|
|US7699791B2 (en)||2001-06-12||2010-04-20||Pelikan Technologies, Inc.||Method and apparatus for improving success rate of blood yield from a fingerstick|
|US8784335B2 (en)||2002-04-19||2014-07-22||Sanofi-Aventis Deutschland Gmbh||Body fluid sampling device with a capacitive sensor|
|US7901362B2 (en)||2002-04-19||2011-03-08||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US9314194B2 (en)||2002-04-19||2016-04-19||Sanofi-Aventis Deutschland Gmbh||Tissue penetration device|
|US7648468B2 (en)||2002-04-19||2010-01-19||Pelikon Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7682318B2 (en)||2001-06-12||2010-03-23||Pelikan Technologies, Inc.||Blood sampling apparatus and method|
|US7371247B2 (en)||2002-04-19||2008-05-13||Pelikan Technologies, Inc||Method and apparatus for penetrating tissue|
|US8337419B2 (en)||2002-04-19||2012-12-25||Sanofi-Aventis Deutschland Gmbh||Tissue penetration device|
|US7297122B2 (en)||2002-04-19||2007-11-20||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7547287B2 (en)||2002-04-19||2009-06-16||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7291117B2 (en)||2002-04-19||2007-11-06||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7976476B2 (en)||2002-04-19||2011-07-12||Pelikan Technologies, Inc.||Device and method for variable speed lancet|
|US8267870B2 (en)||2002-04-19||2012-09-18||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for body fluid sampling with hybrid actuation|
|US7232451B2 (en)||2002-04-19||2007-06-19||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US9248267B2 (en)||2002-04-19||2016-02-02||Sanofi-Aventis Deustchland Gmbh||Tissue penetration device|
|US7226461B2 (en)||2002-04-19||2007-06-05||Pelikan Technologies, Inc.||Method and apparatus for a multi-use body fluid sampling device with sterility barrier release|
|US8360992B2 (en)||2002-04-19||2013-01-29||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for penetrating tissue|
|US7717863B2 (en)||2002-04-19||2010-05-18||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7491178B2 (en)||2002-04-19||2009-02-17||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|WO2002100460A3 (en)||2001-06-12||2003-05-08||Don Alden||Electric lancet actuator|
|US7041068B2 (en)||2001-06-12||2006-05-09||Pelikan Technologies, Inc.||Sampling module device and method|
|US9427532B2 (en)||2001-06-12||2016-08-30||Sanofi-Aventis Deutschland Gmbh||Tissue penetration device|
|US7331931B2 (en)||2002-04-19||2008-02-19||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7909778B2 (en)||2002-04-19||2011-03-22||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7674232B2 (en)||2002-04-19||2010-03-09||Pelikan Technologies, Inc.||Method and apparatus for penetrating tissue|
|US7981056B2 (en)||2002-04-19||2011-07-19||Pelikan Technologies, Inc.||Methods and apparatus for lancet actuation|
|US8221334B2 (en)||2002-04-19||2012-07-17||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for penetrating tissue|
|EP1404235A4 (en)||2001-06-12||2008-08-20||Pelikan Technologies Inc||Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge|
|US7344507B2 (en)||2002-04-19||2008-03-18||Pelikan Technologies, Inc.||Method and apparatus for lancet actuation|
|US8702624B2 (en)||2006-09-29||2014-04-22||Sanofi-Aventis Deutschland Gmbh||Analyte measurement device with a single shot actuator|
|US8574895B2 (en)||2002-12-30||2013-11-05||Sanofi-Aventis Deutschland Gmbh||Method and apparatus using optical techniques to measure analyte levels|
|EP1628567B1 (en)||2003-05-30||2010-08-04||Pelikan Technologies Inc.||Method and apparatus for fluid injection|
|US7850621B2 (en)||2003-06-06||2010-12-14||Pelikan Technologies, Inc.||Method and apparatus for body fluid sampling and analyte sensing|
|CA2529579C (en) *||2003-06-20||2011-01-25||F. Hoffmann-La Roche Ag||Biosensor with multiple electrical functionalities|
|KR100785670B1 (en) *||2003-06-20||2007-12-14||에프. 호프만-라 로슈 아게||Method and reagent for producing narrow, homogenous reagent strips|
|US7452457B2 (en) *||2003-06-20||2008-11-18||Roche Diagnostics Operations, Inc.||System and method for analyte measurement using dose sufficiency electrodes|
|WO2005033659A3 (en)||2003-09-29||2007-01-18||Pelikan Technologies Inc||Method and apparatus for an improved sample capture device|
|WO2005037095A1 (en)||2003-10-14||2005-04-28||Pelikan Technologies, Inc.||Method and apparatus for a variable user interface|
|WO2005040407A1 (en) *||2003-10-24||2005-05-06||Bayer Healthcare Llc||Enzymatic electrochemical biosensor|
|WO2005065414A3 (en)||2003-12-31||2005-12-29||Pelikan Technologies Inc||Method and apparatus for improving fluidic flow and sample capture|
|JP2007523326A (en)||2004-02-06||2007-08-16||バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ||Species that may be oxidized as an internal standard for biosensors, and method of use|
|EP1751546A2 (en)||2004-05-20||2007-02-14||Albatros Technologies GmbH & Co. KG||Printable hydrogel for biosensors|
|US9775553B2 (en)||2004-06-03||2017-10-03||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for a fluid sampling device|
|EP1765194A4 (en)||2004-06-03||2010-09-29||Pelikan Technologies Inc||Method and apparatus for a fluid sampling device|
|WO2006001797A1 (en)||2004-06-14||2006-01-05||Pelikan Technologies, Inc.||Low pain penetrating|
|US7556723B2 (en)||2004-06-18||2009-07-07||Roche Diagnostics Operations, Inc.||Electrode design for biosensor|
|DE112005001154B4 (en) *||2004-06-23||2011-09-29||Tesa Se||Be examined by means of which biological fluids Medical biosensor|
|US8652831B2 (en)||2004-12-30||2014-02-18||Sanofi-Aventis Deutschland Gmbh||Method and apparatus for analyte measurement test time|
|US7822454B1 (en)||2005-01-03||2010-10-26||Pelikan Technologies, Inc.||Fluid sampling device with improved analyte detecting member configuration|
|KR101321296B1 (en)||2005-07-20||2013-10-28||바이엘 헬스케어 엘엘씨||Gated amperometry temperature determination|
|KR101477948B1 (en)||2005-09-30||2014-12-30||바이엘 헬스케어 엘엘씨||Gated voltammetry analysis duration determination|
|RU2499996C2 (en) *||2005-11-14||2013-11-27||Байер Хелткэр Ллк||Analysing sensor reagent having cellulose polymers|
|US8409424B2 (en) *||2006-12-19||2013-04-02||Apex Biotechnology Corp.||Electrochemical test strip, electrochemical test system, and measurement method using the same|
|EP1813937A1 (en) *||2006-01-25||2007-08-01||Boehringer Mannheim Gmbh||Electrochemical biosensor analysis system|
|RU2455925C2 (en) *||2006-02-27||2012-07-20||БАЙЕР ХЕЛТКЭА ЭлЭлСи||Determination of investigated substance with correction to temperature for systems of biosensors|
|US7887682B2 (en) *||2006-03-29||2011-02-15||Abbott Diabetes Care Inc.||Analyte sensors and methods of use|
|US8529751B2 (en)||2006-03-31||2013-09-10||Lifescan, Inc.||Systems and methods for discriminating control solution from a physiological sample|
|US8398443B2 (en) *||2006-04-21||2013-03-19||Roche Diagnostics Operations, Inc.||Biological testing system and connector therefor|
|US7966859B2 (en)||2006-05-03||2011-06-28||Bayer Healthcare Llc||Underfill detection system for a biosensor|
|US7312042B1 (en)||2006-10-24||2007-12-25||Abbott Diabetes Care, Inc.||Embossed cell analyte sensor and methods of manufacture|
|WO2008051742A3 (en)||2006-10-24||2008-06-19||Bayer Healthcare Llc||Transient decay amperometry|
|JP2010513861A (en)||2006-12-15||2010-04-30||コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ||Micro Jer black tonic devices wetting sensitive surface|
|EP2535830A3 (en)||2007-05-30||2014-10-01||Bayer HealthCare LLC||Method and system for managing health data|
|JP4856009B2 (en) *||2007-05-31||2012-01-18||グンゼ株式会社||Biosensor|
|JP4856011B2 (en) *||2007-06-05||2012-01-18||グンゼ株式会社||Biosensor|
|US8778168B2 (en)||2007-09-28||2014-07-15||Lifescan, Inc.||Systems and methods of discriminating control solution from a physiological sample|
|CN101842696A (en) *||2007-10-31||2010-09-22||爱科来株式会社||Analysis tool, analyzer, sample shortage detection method, and sample analysis method|
|JP5812603B2 (en) *||2007-12-10||2015-11-17||バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ||Gradient-based correction|
|US8603768B2 (en) *||2008-01-17||2013-12-10||Lifescan, Inc.||System and method for measuring an analyte in a sample|
|US8431011B2 (en) *||2008-01-31||2013-04-30||Abbott Diabetes Care Inc.||Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip|
|JP2009250806A (en) *||2008-04-07||2009-10-29||Panasonic Corp||Biosensor system, sensor chip and measuring method of concentration of analyte in blood sample|
|WO2009126900A1 (en)||2008-04-11||2009-10-15||Pelikan Technologies, Inc.||Method and apparatus for analyte detecting device|
|US8551320B2 (en)||2008-06-09||2013-10-08||Lifescan, Inc.||System and method for measuring an analyte in a sample|
|KR20110079701A (en) *||2008-09-30||2011-07-07||멘나이 메디컬 테크놀로지즈 리미티드||Sample measurement system|
|CN102238900A (en) *||2008-10-03||2011-11-09||拜尔健康护理有限责任公司||System and method for predicting ambient temperature in a fluid analyte meter|
|JP5738770B2 (en)||2008-12-08||2015-06-24||バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ||Biosensor system with signal conditioning|
|US9375169B2 (en)||2009-01-30||2016-06-28||Sanofi-Aventis Deutschland Gmbh||Cam drive for managing disposable penetrating member actions with a single motor and motor and control system|
|US8617381B2 (en) *||2009-06-23||2013-12-31||Bayer Healthcare Llc||System and apparatus for determining temperatures in a fluid analyte system|
|US20110048972A1 (en) *||2009-08-31||2011-03-03||Lifescan Scotland Limited||Multi-analyte test strip with shared counter/reference electrode and inline electrode configuration|
|CN102597759B (en)||2009-11-10||2016-01-13||拜尔健康护理有限责任公司||Underfill recognition system for a biosensor|
|US8877034B2 (en) *||2009-12-30||2014-11-04||Lifescan, Inc.||Systems, devices, and methods for measuring whole blood hematocrit based on initial fill velocity|
|US8101065B2 (en) *||2009-12-30||2012-01-24||Lifescan, Inc.||Systems, devices, and methods for improving accuracy of biosensors using fill time|
|US20110168575A1 (en) *||2010-01-08||2011-07-14||Roche Diaagnostics Operations, Inc.||Sample characterization based on ac measurement methods|
|US20110208435A1 (en) *||2010-02-25||2011-08-25||Lifescan Scotland Ltd.||Capacitance detection in electrochemical assays|
|KR20130016311A (en) *||2010-03-22||2013-02-14||바이엘 헬쓰케어, 엘엘씨||Residual compensation for a biosensor|
|GB201005357D0 (en)||2010-03-30||2010-05-12||Menai Medical Technologies Ltd||Sampling plate|
|GB201005359D0 (en)||2010-03-30||2010-05-12||Menai Medical Technologies Ltd||Sampling plate|
|US8123572B2 (en)||2010-04-02||2012-02-28||Tyco Electronics Corporation||Electrical components having a contact configured to engage a via of a circuit board|
|US8965476B2 (en)||2010-04-16||2015-02-24||Sanofi-Aventis Deutschland Gmbh||Tissue penetration device|
|US9795747B2 (en)||2010-06-02||2017-10-24||Sanofi-Aventis Deutschland Gmbh||Methods and apparatus for lancet actuation|
|CN104502426B (en)||2010-06-07||2017-05-10||安晟信医疗科技控股公司||A method for determining the concentration of an analyte in a sample|
|WO2011156152A1 (en) *||2010-06-07||2011-12-15||Bayer Healthcare Llc||Slope-based compensation including secondary output signals|
|EP2596115B1 (en)||2010-07-23||2016-03-16||Roche Diagnostics GmbH||Zwitterion buffer containing compositions and uses in electroanalytical devices and methods|
|US8603323B2 (en) *||2010-09-20||2013-12-10||Lifescan, Inc.||Apparatus and process for improved measurements of a monitoring device|
|US8617370B2 (en)||2010-09-30||2013-12-31||Cilag Gmbh International||Systems and methods of discriminating between a control sample and a test fluid using capacitance|
|US8932445B2 (en) *||2010-09-30||2015-01-13||Cilag Gmbh International||Systems and methods for improved stability of electrochemical sensors|
|JP5728568B2 (en) *||2011-02-23||2015-06-03||パナソニックヘルスケアホールディングス株式会社||Biological sample measurement device|
|JP6082396B2 (en)||2011-09-21||2017-02-15||バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ||Bio-sensor with the error compensation|
|WO2013098563A9 (en) *||2011-12-29||2013-10-31||Lifescan Scotland Limited||Accurate analyte measurements for electrochemical test strip based on sensed physical characteristic(s) of the sample containing the analyte|
|GB201206588D0 (en) *||2012-04-13||2012-05-30||Smartcare Technologies Ltd||Improvements in and relating to sample measurement|
|KR101466222B1 (en) *||2012-06-01||2014-12-01||주식회사 아이센스||Electrochemical biosensor with improved accuracy|
|EP3269304A1 (en) *||2012-07-27||2018-01-17||Ascensia Diabetes Care Holdings AG||System and method for detecting used and dried sensors|
|EP2972273A1 (en)||2013-03-15||2016-01-20||Roche Diagnostics GmbH||Methods of using information from recovery pulses in electrochemical analyte measurements as well as devices, apparatuses and systems incorporating the same|
|CN105164523B (en)||2013-03-15||2017-09-12||豪夫迈·罗氏有限公司||Scaling the data used to construct the biosensor algorithm method and a device combining the method, apparatus and system|
|CA2900883C (en)||2013-03-15||2017-10-24||F. Hoffmann-La Roche Ag||Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same|
|CN105247357B (en)||2013-03-15||2017-12-12||豪夫迈·罗氏有限公司||Detection of high levels of antioxidants and methods for analyte concentration from fail-binding substance and its equipment, apparatus and system during the electrochemical measurement|
|US9243276B2 (en)||2013-08-29||2016-01-26||Lifescan Scotland Limited||Method and system to determine hematocrit-insensitive glucose values in a fluid sample|
|US9459231B2 (en)||2013-08-29||2016-10-04||Lifescan Scotland Limited||Method and system to determine erroneous measurement signals during a test measurement sequence|
|JP5702457B2 (en) *||2013-12-06||2015-04-15||パナソニックヘルスケアホールディングス株式会社||Biosensor system, a sensor chip and method of measuring the analyte concentration in a blood sample|
|US9823213B2 (en)||2014-11-10||2017-11-21||Apex Biotechnology Corp.||Electrochemical test strip, measurement system and method for determining sample content in the reactive region of the electrochemical test strip|
Family Cites Families (618)
|Publication number||Priority date||Publication date||Assignee||Title|
|US286735A (en)||1883-10-16||Heineicii eossleb|
|US672094A (en)||1900-08-27||1901-04-16||George Cliffton||Feed-cooker.|
|US2526651A (en)||1945-08-02||1950-10-24||Hydrocarbon Research Inc||Separating powdered catalysts from exothermically reactive gases|
|GB787123A (en)||1954-03-18||1957-12-04||Rheinpreussen Ag||Apparatus for the catalytic gas reactions in liquid media|
|US2883169A (en)||1955-04-29||1959-04-21||Mining Process & Patent Co||Aerating apparatus for flotation pulps|
|US3526480A (en)||1966-12-15||1970-09-01||Xerox Corp||Automated chemical analyzer|
|US3551295A (en)||1967-11-29||1970-12-29||Northrop Corp||Microbiological detection and identification system|
|US3621381A (en)||1968-10-16||1971-11-16||Leeds & Northrup Co||Coulometric system having compensation for temperature induced viscosity changes|
|BE754658A (en)||1969-08-12||1971-02-10||Merck Patent Gmbh||Indicator lamina, consisting of a capillary impregnated material, and absorbent sheets Shrouded|
|US3644824A (en)||1970-02-09||1972-02-22||Atomic Energy Authority Uk||Polarograph apparatus|
|US3770607A (en)||1970-04-07||1973-11-06||Secretary||Glucose determination apparatus|
|US3661748A (en)||1970-04-07||1972-05-09||Instrumentation Labor Inc||Fault sensing instrumentation|
|US3656543A (en)||1970-05-25||1972-04-18||Foster Wheeler Corp||Liquid metal heat exchanger|
|US3919627A (en)||1970-08-06||1975-11-11||Gerald F Allen||Conductivity measuring method and apparatus utilizing coaxial electrode cells|
|US3925183A (en)||1972-06-16||1975-12-09||Energetics Science||Gas detecting and quantitative measuring device|
|US3776832A (en)||1970-11-10||1973-12-04||Energetics Science||Electrochemical detection cell|
|US3720093A (en)||1970-12-03||1973-03-13||Us Navy||Carbon dioxide indicating meter|
|US3718568A (en)||1971-05-21||1973-02-27||Instrumentation Labor Inc||Electrochemical sensor instrumentation|
|CA978457A (en)||1971-09-09||1975-11-25||Hoffmann-La Roche Limited||Enzyme electrode|
|US3763422A (en)||1971-10-21||1973-10-02||Corning Glass Works||Method and apparatus for electrochemical analysis of small samples of blood|
|US3870099A (en)||1972-05-19||1975-03-11||Atomic Energy Commission||Seal assembly|
|US3902970A (en)||1973-07-30||1975-09-02||Leeds & Northrup Co||Flow-through amperometric measuring system and method|
|NL7408519A (en)||1973-08-06||1975-02-10||Hoffmann La Roche||A method for measuring the concentration of substrates and a device for applying this method.|
|US4065263A (en)||1976-04-02||1977-12-27||Woodbridge Iii Richard G||Analytical test strip apparatus|
|US3993947B1 (en)||1974-09-19||1992-07-14||Drexelbrook Controls|
|US3937615A (en)||1974-12-17||1976-02-10||Leeds & Northrup Company||Auto-ranging glucose measuring system|
|FR2295419B1 (en)||1974-12-21||1980-01-25||Kyoto Daiichi Kagaku Kk|
|US4052596A (en)||1974-12-23||1977-10-04||Hycel, Inc.||Automatic hematology analyzer|
|US4060127A (en)||1975-04-15||1977-11-29||Nikolai Ivanovich Savin||Shell-and-tube heat exchanger|
|US4008448A (en)||1975-10-03||1977-02-15||Polaroid Corporation||Solenoid with selectively arrestible plunger movement|
|US4230537A (en)||1975-12-18||1980-10-28||Monsanto Company||Discrete biochemical electrode system|
|US4040908A (en)||1976-03-12||1977-08-09||Children's Hospital Medical Center||Polarographic analysis of cholesterol and other macromolecular substances|
|US4053381A (en)||1976-05-19||1977-10-11||Eastman Kodak Company||Device for determining ionic activity of components of liquid drops|
|US4123701A (en)||1976-07-01||1978-10-31||United States Surgical Corporation||Disposable sample card having a well with electrodes for testing a liquid sample|
|US4092635A (en)||1976-09-20||1978-05-30||Baxter Travenol Laboratories, Inc.||Humidity sensor alarm unit|
|US4127448A (en)||1977-02-28||1978-11-28||Schick Karl G||Amperometric-non-enzymatic method of determining sugars and other polyhydroxy compounds|
|DE2826517C2 (en)||1977-06-17||1984-08-23||Unisearch Ltd., Kensington, New South Wales, Au|
|JPS5912135B2 (en)||1977-09-28||1984-03-21||Matsushita Electric Ind Co Ltd|
|JPS5460996A (en)||1977-10-22||1979-05-16||Mitsubishi Chem Ind||Method of measuring amount of sugar|
|US4214968A (en)||1978-04-05||1980-07-29||Eastman Kodak Company||Ion-selective electrode|
|DE2817363C2 (en)||1978-04-20||1984-01-26||Siemens Ag, 1000 Berlin Und 8000 Muenchen, De|
|DE2823485C2 (en)||1978-05-30||1986-03-27||Albert Prof. Dr. 3550 Marburg De Huch|
|US4184936A (en)||1978-07-24||1980-01-22||Eastman Kodak Company||Device for determining ionic activity|
|US4233029A (en)||1978-10-25||1980-11-11||Eastman Kodak Company||Liquid transport device and method|
|CA1129498A (en)||1978-10-25||1982-08-10||Richard L. Columbus||Structural configuration and method for transport of a liquid drop through an ingress aperture|
|US4225410A (en)||1978-12-04||1980-09-30||Technicon Instruments Corporation||Integrated array of electrochemical sensors|
|US4329642A (en)||1979-03-09||1982-05-11||Siliconix, Incorporated||Carrier and test socket for leadless integrated circuit|
|US4273134A (en)||1979-05-22||1981-06-16||Biochem International Inc.||Fixation ring assembly and method of assembling a sensor head|
|US4273639A (en)||1979-06-20||1981-06-16||Eastman Kodak Company||Capillary bridge in apparatus for determining ionic activity|
|US4297569A (en)||1979-06-28||1981-10-27||Datakey, Inc.||Microelectronic memory key with receptacle and systems therefor|
|US4265250A (en)||1979-07-23||1981-05-05||Battle Research And Development Associates||Electrode|
|US4413407A (en)||1980-03-10||1983-11-08||Eastman Kodak Company||Method for forming an electrode-containing device with capillary transport between electrodes|
|US4263343A (en)||1979-08-13||1981-04-21||Eastman Kodak Company||Reference elements for ion-selective membrane electrodes|
|US4303887A (en)||1979-10-29||1981-12-01||United States Surgical Corporation||Electrical liquid conductivity measuring system|
|US4301412A (en)||1979-10-29||1981-11-17||United States Surgical Corporation||Liquid conductivity measuring system and sample cards therefor|
|US4628193A (en)||1980-01-30||1986-12-09||Blum Alvin S||Code reading operations supervisor|
|US4323536A (en)||1980-02-06||1982-04-06||Eastman Kodak Company||Multi-analyte test device|
|US4816224B1 (en)||1980-08-05||1992-03-10||Boehringer Mannheim Gmbh|
|DE3029579C2 (en)||1980-08-05||1985-12-12||Boehringer Mannheim Gmbh, 6800 Mannheim, De|
|US4407959A (en)||1980-10-29||1983-10-04||Fuji Electric Co., Ltd.||Blood sugar analyzing apparatus|
|US4413628A (en)||1980-11-19||1983-11-08||Tamulis Walter G||pH Monitor electrode electrolyte cartridge|
|US4420564A (en)||1980-11-21||1983-12-13||Fuji Electric Company, Ltd.||Blood sugar analyzer having fixed enzyme membrane sensor|
|DE3047782A1 (en)||1980-12-18||1982-07-08||Draegerwerk Ag||Circuit arrangement for the correction of the sensorausgangsgroesse|
|US4426451A (en)||1981-01-28||1984-01-17||Eastman Kodak Company||Multi-zoned reaction vessel having pressure-actuatable control means between zones|
|US4436094A (en)||1981-03-09||1984-03-13||Evreka, Inc.||Monitor for continuous in vivo measurement of glucose concentration|
|DE3272121D1 (en)||1981-05-07||1986-08-28||Ottosensors Corp||Mecidal trial|
|US4440175A (en)||1981-08-10||1984-04-03||University Patents, Inc.||Membrane electrode for non-ionic species|
|DE3133826A1 (en)||1981-08-27||1983-03-10||Boehringer Mannheim Gmbh||Analysis test strip and process for its manufacture|
|DE3137174A1 (en)||1981-09-18||1983-04-07||Boehringer Mannheim Gmbh||A device for optical recognition of a coding on a diagnostic test strips|
|DE3278334D1 (en)||1981-10-23||1988-05-19||Genetics Int Inc||Sensor for components of a liquid mixture|
|US4431004A (en)||1981-10-27||1984-02-14||Bessman Samuel P||Implantable glucose sensor|
|US4642295A (en)||1981-12-23||1987-02-10||Baker John R||Methods of determining fructosamine levels in blood samples|
|DE3202067C2 (en)||1982-01-23||1984-06-20||Holger Dr. 5100 Aachen De Kiesewetter|
|DE3228551A1 (en)||1982-07-30||1984-02-02||Siemens Ag||Method for determining the glucose concentration|
|DE3228542A1 (en)||1982-07-30||1984-02-02||Siemens Ag||A method for determining the concentration electrochemically metabolizable substances|
|US4571292A (en)||1982-08-12||1986-02-18||Case Western Reserve University||Apparatus for electrochemical measurements|
|US4467386A (en)||1982-11-17||1984-08-21||Rca Corporation||Fail-safe sensor circuit|
|DE3245318C3 (en)||1982-12-08||1996-06-20||Bayer Ag||Process for carrying out reactions under pressure with suspended catalysts|
|US4679562A (en)||1983-02-16||1987-07-14||Cardiac Pacemakers, Inc.||Glucose sensor|
|US5682884A (en)||1983-05-05||1997-11-04||Medisense, Inc.||Strip electrode with screen printing|
|CA1219040A (en)||1983-05-05||1987-03-10||Elliot V. Plotkin||Measurement of enzyme-catalysed reactions|
|CA1226036A (en)||1983-05-05||1987-08-25||Irving J. Higgins||Analytical equipment and sensor electrodes therefor|
|US5509410A (en)||1983-06-06||1996-04-23||Medisense, Inc.||Strip electrode including screen printing of a single layer|
|DE3326689A1 (en)||1983-07-23||1985-01-31||Boehringer Mannheim Gmbh||A method and apparatus for manufacturing a test strip|
|US4517291A (en)||1983-08-15||1985-05-14||E. I. Du Pont De Nemours And Company||Biological detection process using polymer-coated electrodes|
|US4552458A (en)||1983-10-11||1985-11-12||Eastman Kodak Company||Compact reflectometer|
|DE3475834D1 (en)||1983-10-18||1989-02-02||Leo Ab||cuvette|
|US4703017C1 (en)||1984-02-14||2001-12-04||Becton Dickinson Co||Solid phase assay with visual readout|
|DE3407754A1 (en)||1984-03-02||1985-09-12||Boehringer Mannheim Gmbh||Apparatus for determining dimensions of the diffuse reflexionsvermoegens a smaller probenflaeche|
|GB8406752D0 (en)||1984-03-15||1984-04-18||Unilever Plc||Chemical and clinical tests|
|US4849330A (en)||1984-04-27||1989-07-18||Molecular Devices Corporation||Photoresponsive redox detection and discrimination|
|US5141868A (en)||1984-06-13||1992-08-25||Internationale Octrooi Maatschappij "Octropa" Bv||Device for use in chemical test procedures|
|CA1231136A (en)||1984-06-13||1988-01-05||Ian A. Shanks||Capillary action chemical test device|
|JPS6134031A (en)||1984-07-26||1986-02-18||Nippon Paint Co Ltd||Surface treatment apparatus|
|US4820399A (en)||1984-08-31||1989-04-11||Shimadzu Corporation||Enzyme electrodes|
|US4648665A (en)||1984-10-16||1987-03-10||Amp Incorporated||Electronic key assemblies|
|WO1986002732A1 (en)||1984-10-31||1986-05-09||Unilever Plc||Apparatus for use in electrical, e.g. electrochemical, measurement procedures, and its production and use, and composite assemblies incorporating the apparatus|
|US4713347A (en)||1985-01-14||1987-12-15||Sensor Diagnostics, Inc.||Measurement of ligand/anti-ligand interactions using bulk conductance|
|GB8504521D0 (en)||1985-02-21||1985-03-27||Genetics Int Inc||Electrochemical assay|
|US5279294A (en) *||1985-04-08||1994-01-18||Cascade Medical, Inc.||Medical diagnostic system|
|US4652830A (en)||1985-04-18||1987-03-24||Eg&G Ocean Products, Inc.||Analyzer for comparative measurements of bulk conductivity|
|US4671288A (en)||1985-06-13||1987-06-09||The Regents Of The University Of California||Electrochemical cell sensor for continuous short-term use in tissues and blood|
|EP0230472B2 (en)||1985-06-21||2000-12-13||Matsushita Electric Industrial Co., Ltd.||Biosensor and method of manufacturing same|
|US4938860A (en)||1985-06-28||1990-07-03||Miles Inc.||Electrode for electrochemical sensors|
|DE3525986C2 (en)||1985-07-20||1988-11-17||Hochtemperatur-Kernkraftwerk Gmbh (Hkg) Gemeinsames Europaeisches Unternehmen, 4700 Hamm, De|
|US4686479A (en)||1985-07-22||1987-08-11||Young Chung C||Apparatus and control kit for analyzing blood sample values including hematocrit|
|US4806312A (en)||1985-08-28||1989-02-21||Miles Inc.||Multizone analytical element having detectable signal concentrating zone|
|US4806311A (en)||1985-08-28||1989-02-21||Miles Inc.||Multizone analytical element having labeled reagent concentration zone|
|US4734184A (en)||1985-08-29||1988-03-29||Diamond Sensor Systems, Inc.||Self-activating hydratable solid-state electrode apparatus|
|US4805624A (en)||1985-09-09||1989-02-21||The Montefiore Hospital Association Of Western Pa||Low-potential electrochemical redox sensors|
|EP0215669A3 (en)||1985-09-17||1989-08-30||Seiko Instruments Inc.||Analytical device and method for analysis of biochemicals, microbes and cells|
|US5500350A (en) *||1985-10-30||1996-03-19||Celltech Limited||Binding assay device|
|US4714874A (en)||1985-11-12||1987-12-22||Miles Inc.||Test strip identification and instrument calibration|
|US4935106A (en)||1985-11-15||1990-06-19||Smithkline Diagnostics, Inc.||Ion selective/enzymatic electrode medical analyzer device and method of use|
|GB8608700D0 (en)||1986-04-10||1986-05-14||Genetics Int Inc||Measurement of electroactive species in solution|
|US4795542A (en)||1986-04-24||1989-01-03||St. Jude Medical, Inc.||Electrochemical concentration detector device|
|FR2598227B1 (en)||1986-04-30||1989-07-28||Bio Merieux||Method for detection and / or identification of a biological substance in a liquid medium by means of electrical measurements and device intended for carrying out this method|
|US5066372A (en)||1986-05-02||1991-11-19||Ciba Corning Diagnostics Corp.||Unitary multiple electrode sensor|
|US4703756A (en)||1986-05-06||1987-11-03||The Regents Of The University Of California||Complete glucose monitoring system with an implantable, telemetered sensor module|
|US5324335A (en)||1986-05-08||1994-06-28||Rentech, Inc.||Process for the production of hydrocarbons|
|US4731726A (en)||1986-05-19||1988-03-15||Healthware Corporation||Patient-operated glucose monitor and diabetes management system|
|GB8612861D0 (en)||1986-05-27||1986-07-02||Cambridge Life Sciences||Immobilised enzyme biosensors|
|JPH0419503B2 (en)||1986-06-27||1992-03-30||Terumo Corp|
|GB8618022D0 (en)||1986-07-23||1986-08-28||Unilever Plc||Electrochemical measurements|
|US4935346A (en)||1986-08-13||1990-06-19||Lifescan, Inc.||Minimum procedure system for the determination of analytes|
|US5049487A (en)||1986-08-13||1991-09-17||Lifescan, Inc.||Automated initiation of timing of reflectance readings|
|US5059394A (en)||1986-08-13||1991-10-22||Lifescan, Inc.||Analytical device for the automated determination of analytes in fluids|
|US4865873A (en)||1986-09-15||1989-09-12||General Electric Company||Electroless deposition employing laser-patterned masking layer|
|US4897162A (en)||1986-11-14||1990-01-30||The Cleveland Clinic Foundation||Pulse voltammetry|
|DE3643263C2 (en)||1986-12-18||1989-03-09||Horst Dipl.-Ing. 7500 Karlsruhe De Hommel|
|US4750496A (en)||1987-01-28||1988-06-14||Xienta, Inc.||Method and apparatus for measuring blood glucose concentration|
|GB2201248B (en)||1987-02-24||1991-04-17||Ici Plc||Enzyme electrode sensors|
|US4759828A (en)||1987-04-09||1988-07-26||Nova Biomedical Corporation||Glucose electrode and method of determining glucose|
|CA1315181C (en)||1987-04-13||1993-03-30||Joel M. Blatt||Test strip device with volume metering capillary gap|
|US4956275A (en)||1987-04-14||1990-09-11||Molecular Devices Corporation||Migratory detection immunoassay|
|EP0290683A3 (en)||1987-05-01||1988-12-14||Diva Medical Systems B.V.||Diabetes management system and apparatus|
|DE3715938A1 (en)||1987-05-13||1988-11-24||Boehringer Mannheim Gmbh||test strip capacities for|
|US4975647A (en)||1987-06-01||1990-12-04||Nova Biomedical Corporation||Controlling machine operation with respect to consumable accessory units|
|US4797256A (en)||1987-06-05||1989-01-10||Boehringer Mannheim Corporation||Registration device for blood test strips|
|US5447837A (en)||1987-08-05||1995-09-05||Calypte, Inc.||Multi-immunoassay diagnostic system for antigens or antibodies or both|
|US4812210A (en)||1987-10-16||1989-03-14||The United States Department Of Energy||Measuring surfactant concentration in plating solutions|
|US4929426A (en)||1987-11-02||1990-05-29||Biologix, Inc.||Portable blood chemistry measuring apparatus|
|US4940945A (en)||1987-11-02||1990-07-10||Biologix Inc.||Interface circuit for use in a portable blood chemistry measuring apparatus|
|DE3742786A1 (en)||1987-12-17||1989-06-29||Boehringer Mannheim Gmbh||Analysis system for determining a component of a fluid|
|US4832814A (en)||1987-12-28||1989-05-23||E. I. Du Pont De Nemours And Company||Electrofusion cell and method of making the same|
|DE68924026D1 (en)||1988-03-31||1995-10-05||Matsushita Electric Ind Co Ltd||Biosensor and its production.|
|US4877580A (en)||1988-02-09||1989-10-31||Technimed Corporation||Assay kit including an analyte test strip and a color comparator|
|JP2641236B2 (en)||1988-03-09||1997-08-13||雪印乳業株式会社||Sterilization method and a fluidized bed with the reactor of the immobilized biocatalyst|
|US5128015A (en)||1988-03-15||1992-07-07||Tall Oak Ventures||Method and apparatus for amperometric diagnostic analysis|
|US5108564A (en)||1988-03-15||1992-04-28||Tall Oak Ventures||Method and apparatus for amperometric diagnostic analysis|
|US4954087A (en)||1988-04-27||1990-09-04||I-Stat Corporation||Static-free interrogating connector for electric components|
|US5112758A (en)||1988-05-09||1992-05-12||Epitope, Inc.||Treating body fluids for diagnostic testing|
|ES2085854T3 (en)||1988-08-02||1996-06-16||Abbott Lab||Method and device production calibration data for analysis.|
|US5075077A (en)||1988-08-02||1991-12-24||Abbott Laboratories||Test card for performing assays|
|US5096669A (en) *||1988-09-15||1992-03-17||I-Stat Corporation||Disposable sensing device for real time fluid analysis|
|US5439826A (en)||1988-12-02||1995-08-08||Bio-Tek Instruments, Inc.||Method of distinguishing among strips for different assays in an automated instrument|
|US5039618A (en)||1989-02-02||1991-08-13||Hybrivet Systems, Inc.||Test swab cartridge type device and method for detecting lead and cadmium|
|US5118183A (en)||1989-02-10||1992-06-02||X-Rite, Incorporated||Automated strip reader densitometer|
|JP2654682B2 (en)||1989-02-17||1997-09-17||富士写真フイルム株式会社||Biochemical analysis apparatus, biochemical analysis correction method and the correction value recording medium|
|US5053199A (en)||1989-02-21||1991-10-01||Boehringer Mannheim Corporation||Electronically readable information carrier|
|US5269891A (en)||1989-03-09||1993-12-14||Novo Nordisk A/S||Method and apparatus for determination of a constituent in a fluid|
|US5312762A (en)||1989-03-13||1994-05-17||Guiseppi Elie Anthony||Method of measuring an analyte by measuring electrical resistance of a polymer film reacting with the analyte|
|DE3910262C1 (en)||1989-03-30||1990-11-08||Deutsche Gesellschaft Fuer Wiederaufarbeitung Von Kernbrennstoffen Mbh, 3000 Hannover, De|
|DE3911539A1 (en)||1989-04-08||1990-10-11||Boehringer Mannheim Gmbh||Testtraeger-analysis system|
|US4960546B1 (en)||1989-04-19||1996-04-09||Environmental Dynamics Inc||Diffuser mounting arrangement for waste water aeration systems|
|US5234813A (en)||1989-05-17||1993-08-10||Actimed Laboratories, Inc.||Method and device for metering of fluid samples and detection of analytes therein|
|DE4011428A1 (en)||1989-05-24||1990-11-29||Neubrandenburg Pharma Veb||Bio-catalyst substrate concn. determn. - based on potentiometric and amperometric cell with bio-tensions|
|DE59005357D1 (en)||1989-07-07||1994-05-19||Disetronic Holding Ag Burgdorf||Glucose meter.|
|US4976724A (en)||1989-08-25||1990-12-11||Lifescan, Inc.||Lancet ejector mechanism|
|US5306623A (en)||1989-08-28||1994-04-26||Lifescan, Inc.||Visual blood glucose concentration test strip|
|US5620863A (en)||1989-08-28||1997-04-15||Lifescan, Inc.||Blood glucose strip having reduced side reactions|
|EP0415679A3 (en)||1989-08-28||1991-07-03||Lifescan Inc||Blood separation and analyte detection techniques|
|US6395227B1 (en)||1989-08-28||2002-05-28||Lifescan, Inc.||Test strip for measuring analyte concentration over a broad range of sample volume|
|US5018164A (en)||1989-09-12||1991-05-21||Hughes Aircraft Company||Excimer laser ablation method and apparatus for microcircuit fabrication|
|JP2665806B2 (en)||1989-09-13||1997-10-22||株式会社豊田中央研究所||Hematocrit measurement device|
|US5639671A (en)||1989-09-18||1997-06-17||Biostar, Inc.||Methods for optimizing of an optical assay device|
|DE3940152A1 (en)||1989-12-05||1991-06-06||Boehringer Mannheim Gmbh||multiple test strip Test strip evaluation for|
|US5508171A (en)||1989-12-15||1996-04-16||Boehringer Mannheim Corporation||Assay method with enzyme electrode system|
|US4999582A (en) *||1989-12-15||1991-03-12||Boehringer Mannheim Corp.||Biosensor electrode excitation circuit|
|US4999632A (en) *||1989-12-15||1991-03-12||Boehringer Mannheim Corporation||Analog to digital conversion with noise reduction|
|US4963814A (en)||1989-12-15||1990-10-16||Boehringer Mannheim Corporation||Regulated bifurcated power supply|
|KR0171222B1 (en) *||1989-12-15||1999-02-18||스티브 올드함||Redox mediator reagent and biosensor|
|US5762770A (en)||1994-02-21||1998-06-09||Boehringer Mannheim Corporation||Electrochemical biosensor test strip|
|US5243516A (en)||1989-12-15||1993-09-07||Boehringer Mannheim Corporation||Biosensing instrument and method|
|DE4003194A1 (en)||1990-02-03||1991-08-08||Boehringer Mannheim Gmbh||Electrochemical determn. of analytes - using oxido-reductase and substance of being reduced, which is re-oxidised on the electrode|
|US5286362A (en) *||1990-02-03||1994-02-15||Boehringer Mannheim Gmbh||Method and sensor electrode system for the electrochemical determination of an analyte or an oxidoreductase as well as the use of suitable compounds therefor|
|US5141850A (en)||1990-02-07||1992-08-25||Hygeia Sciences, Inc.||Porous strip form assay device method|
|US5187100A (en) *||1990-05-29||1993-02-16||Lifescan, Inc.||Dispersion to limit penetration of aqueous solutions into a membrane|
|US5250439A (en)||1990-07-19||1993-10-05||Miles Inc.||Use of conductive sensors in diagnostic assays|
|JPH0820412B2 (en) *||1990-07-20||1996-03-04||松下電器産業株式会社||Quantitative analysis method using the disposable sensor, and a device|
|US5112455A (en)||1990-07-20||1992-05-12||I Stat Corporation||Method for analytically utilizing microfabricated sensors during wet-up|
|US5124661A (en)||1990-07-23||1992-06-23||I-Stat Corporation||Reusable test unit for simulating electrochemical sensor signals for quality assurance of portable blood analyzer instruments|
|US5182707A (en) *||1990-07-23||1993-01-26||Healthdyne, Inc.||Apparatus for recording reagent test strip data by comparison to color lights on a reference panel|
|US5569591A (en)||1990-08-03||1996-10-29||University College Of Wales Aberystwyth||Analytical or monitoring apparatus and method|
|US5120421A (en)||1990-08-31||1992-06-09||The United States Of America As Represented By The United States Department Of Energy||Electrochemical sensor/detector system and method|
|US5526808A (en)||1990-10-04||1996-06-18||Microcor, Inc.||Method and apparatus for noninvasively determining hematocrit|
|US5642734A (en)||1990-10-04||1997-07-01||Microcor, Inc.||Method and apparatus for noninvasively determining hematocrit|
|DE4041905A1 (en) *||1990-12-27||1992-07-02||Boehringer Mannheim Gmbh||Testtraeger-analysis system|
|US5126952A (en)||1991-01-22||1992-06-30||Eastman Kodak Company||Bar coding calibration|
|EP0572571B1 (en) *||1991-02-27||2003-12-03||Roche Diagnostics Corporation||Apparatus and method for analyzing body fluids|
|US5232668A (en)||1991-02-27||1993-08-03||Boehringer Mannheim Corporation||Test strip holding and reading mechanism for a meter|
|US5246858A (en)||1991-02-27||1993-09-21||Boehringer Mannheim Corporation||Apparatus and method for analyzing a body fluid|
|DE69232284T2 (en) *||1991-02-27||2002-06-13||Roche Diagnostics Corp||Transmission method with micro computer-controlled instruments|
|US5593852A (en)||1993-12-02||1997-01-14||Heller; Adam||Subcutaneous glucose electrode|
|US5192415A (en) *||1991-03-04||1993-03-09||Matsushita Electric Industrial Co., Ltd.||Biosensor utilizing enzyme and a method for producing the same|
|DE4117847A1 (en)||1991-05-31||1992-12-03||Lre Relais & Elektronik Gmbh||Evaluating bar coded optical information - subjecting output from sensor to peak and min. valve generation with comparison process|
|US5232516A (en)||1991-06-04||1993-08-03||Implemed, Inc.||Thermoelectric device with recuperative heat exchangers|
|GB9113211D0 (en) *||1991-06-19||1991-08-07||Hypoguard Uk Ltd||Support membrane|
|DE4123348A1 (en)||1991-07-15||1993-01-21||Boehringer Mannheim Gmbh||Electrochemical analysis system|
|US5179288A (en) *||1991-09-30||1993-01-12||Ortho Pharmaceutical Corporation||Apparatus and method for measuring a bodily constituent|
|US5264103A (en)||1991-10-18||1993-11-23||Matsushita Electric Industrial Co., Ltd.||Biosensor and a method for measuring a concentration of a substrate in a sample|
|US5220920A (en)||1991-11-08||1993-06-22||Via Medical Corporation||Electrochemical measurement system having interference reduction circuit|
|DE69228291T2 (en)||1991-11-19||1999-06-02||Houston Advanced Res Center||Method and apparatus for detection of molecules|
|JP3135959B2 (en)||1991-12-12||2001-02-19||アークレイ株式会社||Biosensors and separation quantification method using the same|
|US5217594A (en)||1992-01-15||1993-06-08||Enzyme Technology Research Group, Inc.||Convenient determination of trace lead in whole blood and other fluids|
|EP0555045B1 (en)||1992-02-03||1997-10-08||Lifescan, Inc.||Improved oxidative coupling dye for spectrophotometric quantitative analysis of analytes|
|US5635364A (en)||1992-03-27||1997-06-03||Abbott Laboratories||Assay verification control for an automated analytical system|
|US5296192A (en) *||1992-04-03||1994-03-22||Home Diagnostics, Inc.||Diagnostic test strip|
|US5353351A (en)||1992-06-09||1994-10-04||At&T Bell Laboratories||Secure teleconferencing|
|GB9215733D0 (en)||1992-07-24||1992-09-09||British Tech Group||Method of and apparatus for determining a property of a sample|
|CA2105940C (en)||1992-10-05||2001-12-25||Robert M. Koros||Bubble column, tube side slurry process and apparatus|
|US5387327A (en)||1992-10-19||1995-02-07||Duquesne University Of The Holy Ghost||Implantable non-enzymatic electrochemical glucose sensor|
|US5508200A (en)||1992-10-19||1996-04-16||Tiffany; Thomas||Method and apparatus for conducting multiple chemical assays|
|US5342790A (en)||1992-10-30||1994-08-30||Becton Dickinson And Company||Apparatus for indirect fluorescent assay of blood samples|
|US5389215A (en) *||1992-11-05||1995-02-14||Nippon Telegraph And Telephone Corporation||Electrochemical detection method and apparatus therefor|
|JP2954436B2 (en)||1992-11-11||1999-09-27||株式会社日立製作所||Test strip supply apparatus and analyzer using the same|
|US6168563B1 (en) *||1992-11-17||2001-01-02||Health Hero Network, Inc.||Remote health monitoring and maintenance system|
|US5371687A (en) *||1992-11-20||1994-12-06||Boehringer Mannheim Corporation||Glucose test data acquisition and management system|
|CA2103325C (en)||1992-11-23||2004-07-20||Kirk W. Johnson||Techniques to improve the performance of electrochemical sensors|
|US5344754A (en)||1993-01-13||1994-09-06||Avocet Medical, Inc.||Assay timed by electrical resistance change and test strip|
|US5599849A (en)||1993-01-27||1997-02-04||Sasol Chemical Industries (Proprietary) Limited||Process for producing liquid and, optionally, gaseous products from gaseous reactants|
|US5515847A (en)||1993-01-28||1996-05-14||Optiscan, Inc.||Self-emission noninvasive infrared spectrophotometer|
|FR2701117B1 (en) *||1993-02-04||1995-03-10||Asulab Sa||System of electrochemical measurement multizone sensor, and its application to glucose analysis.|
|WO1994023018A1 (en)||1993-03-29||1994-10-13||Isk Biosciences Corporation||Immunoassay for tetrachloroisophthalonitrile (chlorothalonil®), its derivatives and breakdown products|
|DE4310583A1 (en)||1993-03-31||1994-10-06||Boehringer Mannheim Gmbh||Test strip analysis system|
|DE4313253A1 (en)||1993-04-23||1994-10-27||Boehringer Mannheim Gmbh||System for the analysis of liquid samples ingredients|
|EP0622626B1 (en)||1993-04-23||2002-03-06||Boehringer Mannheim Gmbh||System for analysing the components of fluid samples|
|US5376254A (en)||1993-05-14||1994-12-27||Fisher; Arkady V.||Potentiometric electrochemical device for qualitative and quantitative analysis|
|US5843691A (en)||1993-05-15||1998-12-01||Lifescan, Inc.||Visually-readable reagent test strip|
|EP0700520B1 (en)||1993-05-29||1997-07-30||Cambridge Life Sciences Plc||Sensors based on polymer transformation|
|DE4318519C2 (en)||1993-06-03||1996-11-28||Fraunhofer Ges Forschung||An electrochemical sensor|
|US5385846A (en) *||1993-06-03||1995-01-31||Boehringer Mannheim Corporation||Biosensor and method for hematocrit determination|
|US5352351A (en) *||1993-06-08||1994-10-04||Boehringer Mannheim Corporation||Biosensing meter with fail/safe procedures to prevent erroneous indications|
|WO1994029705A1 (en) *||1993-06-08||1994-12-22||Boehringer Mannheim Corporation||Biosensing meter which detects proper electrode engagement and distinguishes sample and check strips|
|US5405511A (en)||1993-06-08||1995-04-11||Boehringer Mannheim Corporation||Biosensing meter with ambient temperature estimation method and system|
|US5366609A (en)||1993-06-08||1994-11-22||Boehringer Mannheim Corporation||Biosensing meter with pluggable memory key|
|DE4323672A1 (en)||1993-07-15||1995-01-19||Boehringer Mannheim Gmbh||An apparatus for simultaneous determination of analytes|
|US5527473A (en)||1993-07-15||1996-06-18||Ackerman; Carl D.||Process for performing reactions in a liquid-solid catalyst slurry|
|US5658443A (en)||1993-07-23||1997-08-19||Matsushita Electric Industrial Co., Ltd.||Biosensor and method for producing the same|
|US5413690A (en)||1993-07-23||1995-05-09||Boehringer Mannheim Corporation||Potentiometric biosensor and the method of its use|
|US5508203A (en)||1993-08-06||1996-04-16||Fuller; Milton E.||Apparatus and method for radio frequency spectroscopy using spectral analysis|
|US5792668A (en)||1993-08-06||1998-08-11||Solid State Farms, Inc.||Radio frequency spectral analysis for in-vitro or in-vivo environments|
|US5837546A (en)||1993-08-24||1998-11-17||Metrika, Inc.||Electronic assay device and method|
|WO1995006240A1 (en)||1993-08-24||1995-03-02||Metrika Laboratories, Inc.||Novel disposable electronic assay device|
|US5494831A (en)||1993-08-30||1996-02-27||Hughes Aircraft Company||Electrochemical immunosensor system and methods|
|US5522255A (en)||1993-08-31||1996-06-04||Boehringer Mannheim Corporation||Fluid dose, flow and coagulation sensor for medical instrument|
|US5526111A (en)||1993-08-31||1996-06-11||Boehringer Mannheim Corporation||Method and apparatus for calculating a coagulation characteristic of a sample of blood a blood fraction or a control|
|EP0775311B1 (en)||1993-08-31||2002-07-03||Roche Diagnostics Corporation||Analog heater control for medical instrument|
|US5437772A (en)||1993-11-01||1995-08-01||The Electrosynthesis Co., Inc.||Portable lead detector|
|US5605662A (en) *||1993-11-01||1997-02-25||Nanogen, Inc.||Active programmable electronic devices for molecular biological analysis and diagnostics|
|JPH07128338A (en)||1993-11-02||1995-05-19||Kyoto Daiichi Kagaku:Kk||Convenient blood sugar meter and data managing method therefor|
|US5421189A (en)||1994-01-21||1995-06-06||Ciba Corning Diagnostics Corp.||Electrical connection system for electrochemical sensors|
|US5437999A (en)||1994-02-22||1995-08-01||Boehringer Mannheim Corporation||Electrochemical sensor|
|US5536249A (en)||1994-03-09||1996-07-16||Visionary Medical Products, Inc.||Pen-type injector with a microprocessor and blood characteristic monitor|
|US5583432A (en)||1994-04-11||1996-12-10||Sci-Nostics Limited||Electrical method and apparatus for non-contact determination of physical and/or chemical properties of a sample, particularly of blood|
|DE4417245A1 (en)||1994-04-23||1995-10-26||Lpkf Cad Cam Systeme Gmbh||High resolution structured metallisation prodn.|
|JP3331253B2 (en)||1994-05-10||2002-10-07||バイエルコーポレーション||Specimen dispensing apparatus of an automatic analyzer|
|JP3027306B2 (en)||1994-06-02||2000-04-04||松下電器産業株式会社||Biosensor and a method of manufacturing the same|
|US5700695A (en)||1994-06-30||1997-12-23||Zia Yassinzadeh||Sample collection and manipulation method|
|US5477326A (en)||1994-06-30||1995-12-19||Bayer Corporation||Spectrophotometer arrangement with multi-detector readhead|
|GB9415499D0 (en)||1994-08-01||1994-09-21||Bartlett Philip N||Electrodes and their use in analysis|
|US5922530A (en)||1994-09-08||1999-07-13||Lifescan, Inc.||Stable coupling dye for photometric determination of analytes|
|US5563031A (en)||1994-09-08||1996-10-08||Lifescan, Inc.||Highly stable oxidative coupling dye for spectrophotometric determination of analytes|
|US6335203B1 (en) *||1994-09-08||2002-01-01||Lifescan, Inc.||Optically readable strip for analyte detection having on-strip orientation index|
|DE69524108T2 (en)||1994-09-08||2002-06-06||Lifescan Inc||Analyte detection strip with a standard strip on the|
|US5515170A (en)||1994-09-08||1996-05-07||Lifescan, Inc.||Analyte detection device having a serpentine passageway for indicator strips|
|US5526120A (en)||1994-09-08||1996-06-11||Lifescan, Inc.||Test strip with an asymmetrical end insuring correct insertion for measuring|
|GB9419882D0 (en)||1994-10-03||1994-11-16||Mcnaughtan Arthur||Electrochemical detection system|
|US5597532A (en) *||1994-10-20||1997-01-28||Connolly; James||Apparatus for determining substances contained in a body fluid|
|US5504011A (en)||1994-10-21||1996-04-02||International Technidyne Corporation||Portable test apparatus and associated method of performing a blood coagulation test|
|JPH10508518A (en)||1994-11-04||1998-08-25||イーラン・メディカル・テクノロジーズ・リミテッド||Liquid is regulated by analyte dispensing device and analyte monitoring|
|US5572159A (en)||1994-11-14||1996-11-05||Nexgen, Inc.||Voltage-controlled delay element with programmable delay|
|KR0151203B1 (en)||1994-12-08||1998-12-01||이헌조||Multi-electrode type biosensor|
|US5630986A (en)||1995-01-13||1997-05-20||Bayer Corporation||Dispensing instrument for fluid monitoring sensors|
|US5569608A (en)||1995-01-30||1996-10-29||Bayer Corporation||Quantitative detection of analytes on immunochromatographic strips|
|US6153069A (en)||1995-02-09||2000-11-28||Tall Oak Ventures||Apparatus for amperometric Diagnostic analysis|
|EP0727925A1 (en) *||1995-02-14||1996-08-21||Lpkf Cad/Cam Systeme Gmbh||Process for structured metallizing of the surface of substrates|
|US5567301A (en)||1995-03-01||1996-10-22||Illinois Institute Of Technology||Antibody covalently bound film immunobiosensor|
|US5582697A (en)||1995-03-17||1996-12-10||Matsushita Electric Industrial Co., Ltd.||Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same|
|US5650062A (en)||1995-03-17||1997-07-22||Matsushita Electric Industrial Co., Ltd.||Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same|
|US5788833A (en)||1995-03-27||1998-08-04||California Institute Of Technology||Sensors for detecting analytes in fluids|
|US6170318B1 (en) *||1995-03-27||2001-01-09||California Institute Of Technology||Methods of use for sensor based fluid detection devices|
|JP3498105B2 (en) *||1995-04-07||2004-02-16||アークレイ株式会社||Sensors, measuring methods of using the manufacturing method and sensor|
|US5620579A (en)||1995-05-05||1997-04-15||Bayer Corporation||Apparatus for reduction of bias in amperometric sensors|
|US5656502A (en)||1995-06-07||1997-08-12||Diagnostic Chemicals Limited||Test strip holder and method of use|
|US6413410B1 (en)||1996-06-19||2002-07-02||Lifescan, Inc.||Electrochemical cell|
|KR100491283B1 (en)||1995-06-19||2005-05-24||라이프스캔, 인코포레이티드||Electrochemical cell|
|US5856174A (en)||1995-06-29||1999-01-05||Affymetrix, Inc.||Integrated nucleic acid diagnostic device|
|US5611900A (en)||1995-07-20||1997-03-18||Michigan State University||Microbiosensor used in-situ|
|US5698083A (en)||1995-08-18||1997-12-16||Regents Of The University Of California||Chemiresistor urea sensor|
|WO1997008544A1 (en) *||1995-08-22||1997-03-06||Andcare, Inc.||Handheld electromonitor device|
|US5786584A (en)||1995-09-06||1998-07-28||Eli Lilly And Company||Vial and cartridge reading device providing audio feedback for a blood glucose monitoring system|
|US5658802A (en)||1995-09-07||1997-08-19||Microfab Technologies, Inc.||Method and apparatus for making miniaturized diagnostic arrays|
|US5650061A (en)||1995-09-18||1997-07-22||The Regents Of The University Of California||Large amplitude sinusoidal voltammetry|
|US5665215A (en)||1995-09-25||1997-09-09||Bayer Corporation||Method and apparatus for making predetermined events with a biosensor|
|US5628890A (en)||1995-09-27||1997-05-13||Medisense, Inc.||Electrochemical sensor|
|US6689265B2 (en)||1995-10-11||2004-02-10||Therasense, Inc.||Electrochemical analyte sensors using thermostable soybean peroxidase|
|CA2187861C (en)||1995-10-17||2007-04-10||Yeung S. Yu||Blood glucose strip having reduced sensitivity to hematocrit|
|US20030180183A1 (en)||1995-10-30||2003-09-25||Takao Fukuoka||Method for measuring substance and testing piece|
|US6521110B1 (en) *||1995-11-16||2003-02-18||Lifescan, Inc.||Electrochemical cell|
|US6174420B1 (en) *||1996-11-15||2001-01-16||Usf Filtration And Separations Group, Inc.||Electrochemical cell|
|CA2236850C (en) *||1995-11-16||2004-06-01||Alastair Mcindoe Hodges||Electrochemical cell|
|US6632349B1 (en)||1996-11-15||2003-10-14||Lifescan, Inc.||Hemoglobin sensor|
|US6638415B1 (en)||1995-11-16||2003-10-28||Lifescan, Inc.||Antioxidant sensor|
|US6863801B2 (en)||1995-11-16||2005-03-08||Lifescan, Inc.||Electrochemical cell|
|JPH09207343A (en)||1995-11-29||1997-08-12||Matsushita Electric Ind Co Ltd||Laser machining method|
|US5755953A (en)||1995-12-18||1998-05-26||Abbott Laboratories||Interference free biosensor|
|US6309526B1 (en)||1997-07-10||2001-10-30||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|US5748002A (en)||1996-01-26||1998-05-05||Phase Dynamics Inc.||RF probe for montoring composition of substances|
|EP0879412A4 (en)||1996-02-08||2004-08-11||Ambri Ltd||Enzyme detection biosensors|
|US5989917A (en)||1996-02-13||1999-11-23||Selfcare, Inc.||Glucose monitor and test strip containers for use in same|
|US5708247A (en)||1996-02-14||1998-01-13||Selfcare, Inc.||Disposable glucose test strips, and methods and compositions for making same|
|US5605837A (en) *||1996-02-14||1997-02-25||Lifescan, Inc.||Control solution for a blood glucose monitor|
|US6241862B1 (en)||1996-02-14||2001-06-05||Inverness Medical Technology, Inc.||Disposable test strips with integrated reagent/blood separation layer|
|DE19605583A1 (en)||1996-02-15||1997-08-21||Bayer Ag||Electrochemical sensors with improved selectivity and increased sensitivity|
|US5801057A (en)||1996-03-22||1998-09-01||Smart; Wilson H.||Microsampling device and method of construction|
|DE19612680C2 (en)||1996-03-29||2000-02-03||Inst Chemo Biosensorik||Cation-selective sensor|
|US5723284A (en)||1996-04-01||1998-03-03||Bayer Corporation||Control solution and method for testing the performance of an electrochemical device for determining the concentration of an analyte in blood|
|US5962215A (en)||1996-04-05||1999-10-05||Mercury Diagnostics, Inc.||Methods for testing the concentration of an analyte in a body fluid|
|US5890489A (en)||1996-04-23||1999-04-06||Dermal Therapy (Barbados) Inc.||Method for non-invasive determination of glucose in body fluids|
|US6001307A (en) *||1996-04-26||1999-12-14||Kyoto Daiichi Kagaku Co., Ltd.||Device for analyzing a sample|
|DE19621241C2 (en) *||1996-05-25||2000-03-16||Manfred Kessler||Membrane electrode for measuring the concentration of glucose in fluids|
|US5781024A (en)||1996-07-26||1998-07-14||Diametrics Medical, Inc.||Instrument performance verification system|
|US5745308A (en)||1996-07-30||1998-04-28||Bayer Corporation||Methods and apparatus for an optical illuminator assembly and its alignment|
|US5883378A (en)||1996-07-30||1999-03-16||Bayer Corporation||Apparatus and methods for transmitting electrical signals indicative of optical interactions between a light beam and a flowing suspension of particles|
|US5719667A (en) *||1996-07-30||1998-02-17||Bayer Corporation||Apparatus for filtering a laser beam in an analytical instrument|
|US5691486A (en)||1996-07-30||1997-11-25||Bayer Corporation||Apparatus and methods for selecting a variable number of test sample aliquots to mix with respective reagents|
|US5753101A (en)||1996-08-01||1998-05-19||Ludwig; Frank A.||Method of monitoring constituents in conversion coating baths|
|US5958791A (en)||1996-09-27||1999-09-28||Innovative Biotechnologies, Inc.||Interdigitated electrode arrays for liposome-enhanced immunoassay and test device|
|US6358752B1 (en)||1996-09-27||2002-03-19||Cornell Research Foundation, Inc.||Liposome-enhanced test device and method|
|US5925293A (en)||1996-10-04||1999-07-20||General Signal Corporation||Mixer sparging apparatus|
|US5945341A (en)||1996-10-21||1999-08-31||Bayer Corporation||System for the optical identification of coding on a diagnostic test strip|
|GB9622304D0 (en)||1996-10-26||1996-12-18||Univ Manchester||Sensor|
|US5856195A (en) *||1996-10-30||1999-01-05||Bayer Corporation||Method and apparatus for calibrating a sensor element|
|WO1998028623A1 (en)||1996-12-20||1998-07-02||Gamera Bioscience Corporation||An affinity binding-based system for detecting particulates in a fluid|
|JP3394262B2 (en)||1997-02-06||2003-04-07||イー．ヘラー アンド カンパニー||Small volume in vitro analyte sensor|
|EP0859230A1 (en)||1997-02-10||1998-08-19||Cranfield University||Detection of analytes using electrochemistry|
|US7381525B1 (en)||1997-03-07||2008-06-03||Clinical Micro Sensors, Inc.||AC/DC voltage apparatus for detection of nucleic acids|
|US6391558B1 (en)||1997-03-18||2002-05-21||Andcare, Inc.||Electrochemical detection of nucleic acid sequences|
|DE69841786D1 (en)||1997-03-21||2010-09-09||Lifescan Inc||Connecting means for a sensor|
|US6226081B1 (en)||1997-03-24||2001-05-01||Optikos Corporation||Optical height of fill detection system and associated methods|
|DE69836490T2 (en)||1997-03-25||2007-03-08||Lifescan, Inc., Milpitas||Improved electrochemical cell|
|DE19714674A1 (en)||1997-04-09||1998-10-15||Lre Technology Partner Gmbh||Test strips and measuring instrument for use of such|
|US5885839A (en)||1997-04-15||1999-03-23||Lxn Corporation||Methods of determining initiation and variable end points for measuring a chemical reaction|
|US6042714A (en)||1997-05-02||2000-03-28||National Science Council||Method and chemical sensor for determining concentrations of hydrogen peroxide and its precursor in a liquid|
|US6103536A (en)||1997-05-02||2000-08-15||Silver Lake Research Corporation||Internally referenced competitive assays|
|US6391645B1 (en)||1997-05-12||2002-05-21||Bayer Corporation||Method and apparatus for correcting ambient temperature effect in biosensors|
|US5798031A (en)||1997-05-12||1998-08-25||Bayer Corporation||Electrochemical biosensor|
|US5921925A (en)||1997-05-30||1999-07-13||Ndm, Inc.||Biomedical electrode having a disposable electrode and a reusable leadwire adapter that interfaces with a standard leadwire connector|
|US6040195A (en)||1997-06-10||2000-03-21||Home Diagnostics, Inc.||Diagnostic sanitary test strip|
|US6013459A (en) *||1997-06-12||2000-01-11||Clinical Micro Sensors, Inc.||Detection of analytes using reorganization energy|
|US6168957B1 (en) *||1997-06-25||2001-01-02||Lifescan, Inc.||Diagnostic test strip having on-strip calibration|
|EP2015068A1 (en)||1997-07-22||2009-01-14||Kyoto Daiichi Kagaku Co., Ltd.||Concentration measuring apparatus, test strip for the concentration measuring apparatus, and biosensor system|
|JP3375040B2 (en)||1997-07-29||2003-02-10||松下電器産業株式会社||Determination of the substrate|
|CA2244332C (en)||1997-07-30||2002-04-02||Becton, Dickinson And Company||Bonding agent and method of bonding electrode to printed conductive trace|
|CA2300406C (en)||1997-08-13||2007-01-09||Usf Filtration And Separations Group Inc.||Method and apparatus for automatic analysis|
|US6071391A (en)||1997-09-12||2000-06-06||Nok Corporation||Enzyme electrode structure|
|US6121050A (en)||1997-08-29||2000-09-19||Han; Chi-Neng Arthur||Analyte detection systems|
|US6061128A (en)||1997-09-04||2000-05-09||Avocet Medical, Inc.||Verification device for optical clinical assay systems|
|US6129823A (en)||1997-09-05||2000-10-10||Abbott Laboratories||Low volume electrochemical sensor|
|US6259937B1 (en)||1997-09-12||2001-07-10||Alfred E. Mann Foundation||Implantable substrate sensor|
|US6007775A (en)||1997-09-26||1999-12-28||University Of Washington||Multiple analyte diffusion based chemical sensor|
|EP1025442B1 (en)||1997-09-30||2001-11-21||Amira Medical||Analytical device with capillary reagent carrier|
|US6088608A (en)||1997-10-20||2000-07-11||Alfred E. Mann Foundation||Electrochemical sensor and integrity tests therefor|
|FI107080B (en)||1997-10-27||2001-05-31||Nokia Mobile Phones Ltd||Measuring Instruments|
|WO1999023479A1 (en)||1997-10-31||1999-05-14||Technical Chemicals & Products, Inc.||Reflectometer|
|US6102872A (en)||1997-11-03||2000-08-15||Pacific Biometrics, Inc.||Glucose detector and method|
|ES2281143T3 (en)||1997-11-12||2007-09-16||Lightouch Medical, Inc.||Method for non-invasive measurement of an analyte.|
|DE69811268T2 (en)||1997-11-28||2003-07-10||Provalis Dianostics Ltd||System and apparatus for conducting an assay method|
|US6635167B1 (en)||1997-12-04||2003-10-21||Roche Diagnostics Corporation||Apparatus and method for determining the concentration of a component of a sample|
|US6579690B1 (en)||1997-12-05||2003-06-17||Therasense, Inc.||Blood analyte monitoring through subcutaneous measurement|
|US5997817A (en)||1997-12-05||1999-12-07||Roche Diagnostics Corporation||Electrochemical biosensor test strip|
|JP2001527216A (en)||1997-12-19||2001-12-25||アミラ メディカル||Embossed test strip system|
|CA2310021C (en)||1997-12-22||2005-02-15||Roche Diagnostics Corporation||An apparatus and method for determining the concentration of a component in a fluid|
|US7407811B2 (en)||1997-12-22||2008-08-05||Roche Diagnostics Operations, Inc.||System and method for analyte measurement using AC excitation|
|US6262749B1 (en)||1997-12-31||2001-07-17||Acuson Corporation||Ultrasonic system and method for data transfer, storage and/or processing|
|US5971923A (en)||1997-12-31||1999-10-26||Acuson Corporation||Ultrasound system and method for interfacing with peripherals|
|JP3848993B2 (en)||1998-01-06||2006-11-22||アークレイ株式会社||Component of the measuring method and the measuring apparatus in the presence of a coexisting substance|
|WO1999051974A1 (en)||1998-04-02||1999-10-14||Matsushita Electric Industrial Co., Ltd.||Substrate determining method|
|US6485905B2 (en)||1998-02-02||2002-11-26||Signature Bioscience, Inc.||Bio-assay device|
|US6394952B1 (en)||1998-02-03||2002-05-28||Adeza Biomedical Corporation||Point of care diagnostic systems|
|JP3978489B2 (en) *||1998-02-26||2007-09-19||アークレイ株式会社||Blood measurement device|
|US6206282B1 (en)||1998-03-03||2001-03-27||Pyper Products Corporation||RF embedded identification device|
|US6103033A (en)||1998-03-04||2000-08-15||Therasense, Inc.||Process for producing an electrochemical biosensor|
|US6134461A (en)||1998-03-04||2000-10-17||E. Heller & Company||Electrochemical analyte|
|US6878251B2 (en)||1998-03-12||2005-04-12||Lifescan, Inc.||Heated electrochemical cell|
|US6475360B1 (en)||1998-03-12||2002-11-05||Lifescan, Inc.||Heated electrochemical cell|
|CA2265119C (en)||1998-03-13||2002-12-03||Cygnus, Inc.||Biosensor, iontophoretic sampling system, and methods of use thereof|
|US5939609A (en)||1998-03-23||1999-08-17||Conception Technology Incorporated||Multi-use sensor having a controllable number of measurement cycles|
|US6091975A (en)||1998-04-01||2000-07-18||Alza Corporation||Minimally invasive detecting device|
|US6246966B1 (en)||1998-04-06||2001-06-12||Bayer Corporation||Method and apparatus for data management authentication in a clinical analyzer|
|US5995236A (en)||1998-04-13||1999-11-30||Mit Development Corporation||Blood fluid characteristics analysis instrument|
|US6175752B1 (en)||1998-04-30||2001-01-16||Therasense, Inc.||Analyte monitoring device and methods of use|
|US6271044B1 (en)||1998-05-06||2001-08-07||University Of Pittsburgh Of The Commonwealth System Of Higher Education||Method and kit for detecting an analyte|
|GB2337122B (en)||1998-05-08||2002-11-13||Medisense Inc||Test strip|
|DE69910003D1 (en)||1998-05-13||2003-09-04||Cygnus Therapeutic Systems||Monitoring physiological analytes|
|DE69910007D1 (en)||1998-05-13||2003-09-04||Cygnus Therapeutic Systems||Apparatus for predicting physiological measuring values|
|US6526298B1 (en) *||1998-05-18||2003-02-25||Abbott Laboratories||Method for the non-invasive determination of analytes in a selected volume of tissue|
|DE29809191U1 (en)||1998-05-20||1998-08-13||Lre Technology Partner Gmbh||Test strips measuring system|
|US6576117B1 (en)||1998-05-20||2003-06-10||Arkray||Method and apparatus for electrochemical measurement using statistical technique|
|US6246330B1 (en)||1998-05-29||2001-06-12||Wyn Y. Nielsen||Elimination-absorber monitoring system|
|US6287595B1 (en)||1998-06-10||2001-09-11||Delsys Pharmaceuticals Corporation||Biomedical assay device|
|US6077660A (en)||1998-06-10||2000-06-20||Abbott Laboratories||Diagnostic assay requiring a small sample of biological fluid|
|JP3389106B2 (en) *||1998-06-11||2003-03-24||松下電器産業株式会社||The electrochemical analysis element|
|US6022366A (en)||1998-06-11||2000-02-08||Stat Medical Devices Inc.||Lancet having adjustable penetration depth|
|US6294281B1 (en)||1998-06-17||2001-09-25||Therasense, Inc.||Biological fuel cell and method|
|JP2002518998A (en)||1998-06-24||2002-07-02||セラセンス、インク．||Multisensor array and a method for electrochemical recognition nucleotide sequence|
|WO1999067019A1 (en) *||1998-06-24||1999-12-29||Therasense, Inc.||Combinatorial electrochemical syntheses|
|JP2000019147A (en)||1998-07-01||2000-01-21||Nok Corp||Reaction product measuring device|
|US6656702B1 (en)||1998-07-03||2003-12-02||Matsushita Electric Industrial Co., Ltd.||Biosensor containing glucose dehydrogenase|
|GB2339615B (en)||1998-07-14||2001-02-07||Cozart Bioscience Ltd||Screening device and method of screening an immunoassay test|
|US6261519B1 (en)||1998-07-20||2001-07-17||Lifescan, Inc.||Medical diagnostic device with enough-sample indicator|
|US6521182B1 (en)||1998-07-20||2003-02-18||Lifescan, Inc.||Fluidic device for medical diagnostics|
|US6162397A (en)||1998-08-13||2000-12-19||Lifescan, Inc.||Visual blood glucose test strip|
|US6096186A (en)||1998-08-18||2000-08-01||Industrial Scientific Corporation||Method for determining exhaustion of an electrochemical gas sensor|
|DE29814997U1 (en)||1998-08-20||1998-12-03||Lre Technology Partner Gmbh||Teststreifenmeßsystem|
|US6281006B1 (en)||1998-08-24||2001-08-28||Therasense, Inc.||Electrochemical affinity assay|
|US6638716B2 (en)||1998-08-24||2003-10-28||Therasense, Inc.||Rapid amperometric verification of PCR amplification of DNA|
|US6251260B1 (en)||1998-08-24||2001-06-26||Therasense, Inc.||Potentiometric sensors for analytic determination|
|JP4689825B2 (en)||1998-08-26||2011-05-25||センサーズ・フォー・メデセン・アンド・サイエンス・インコーポレーテッド||Optical detection device|
|US6087182A (en)||1998-08-27||2000-07-11||Abbott Laboratories||Reagentless analysis of biological samples|
|US5902731A (en)||1998-09-28||1999-05-11||Lifescan, Inc.||Diagnostics based on tetrazolium compounds|
|US6180416B1 (en) *||1998-09-30||2001-01-30||Cygnus, Inc.||Method and device for predicting physiological values|
|EP1102559B1 (en)||1998-09-30||2003-06-04||Cygnus, Inc.||Method and device for predicting physiological values|
|US6338790B1 (en) *||1998-10-08||2002-01-15||Therasense, Inc.||Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator|
|GB9824627D0 (en)||1998-11-11||1999-01-06||Cambridge Sensors Ltd||Test strips for small volumes|
|US6126609A (en)||1998-11-23||2000-10-03||Keith & Rumph Inventors, Inc.||Apparatus for taking blood samples from a patient|
|US6136610A (en)||1998-11-23||2000-10-24||Praxsys Biosystems, Inc.||Method and apparatus for performing a lateral flow assay|
|GB9825992D0 (en)||1998-11-28||1999-01-20||Moorlodge Biotech Ventures Lim||Electrochemical sensor|
|EP1135678A2 (en)||1998-11-30||2001-09-26||Abbott Laboratories||Analyte test instrument having improved calibration and communications processes|
|US6128519A (en)||1998-12-16||2000-10-03||Pepex Biomedical, Llc||System and method for measuring a bioanalyte such as lactate|
|EP1010894B1 (en)||1998-12-19||2004-03-03||GARDENA Kress + Kastner GmbH||Pond insert with pump|
|US6203952B1 (en)||1999-01-14||2001-03-20||3M Innovative Properties Company||Imaged article on polymeric substrate|
|US6344490B1 (en)||1999-01-22||2002-02-05||Exxon Research And Engineering Company||Removable filter for slurry hydrocarbon synthesis process|
|EP1035503B2 (en)||1999-01-23||2010-03-03||X-ident technology GmbH||RFID-Transponder with printable surface|
|US6565738B1 (en)||1999-01-28||2003-05-20||Abbott Laboratories||Diagnostic test for the measurement of analyte in abiological fluid|
|US6197040B1 (en)||1999-02-23||2001-03-06||Lifescan, Inc.||Lancing device having a releasable connector|
|US6045567A (en)||1999-02-23||2000-04-04||Lifescan Inc.||Lancing device causing reduced pain|
|GB9905148D0 (en)||1999-03-05||1999-04-28||Azur Env Ltd||Method of apparatus for the detection of analytes|
|US6333019B1 (en)||1999-04-29||2001-12-25||Marc-Olivier Coppens||Method for operating a chemical and/or physical process by means of a hierarchical fluid injection system|
|US6150124A (en)||1999-05-20||2000-11-21||Umm Electronics, Inc.||Method for passively determining the application of a sample fluid on an analyte strip|
|US6287451B1 (en)||1999-06-02||2001-09-11||Handani Winarta||Disposable sensor and method of making|
|US6258229B1 (en)||1999-06-02||2001-07-10||Handani Winarta||Disposable sub-microliter volume sensor and method of making|
|US6193873B1 (en) *||1999-06-15||2001-02-27||Lifescan, Inc.||Sample detection to initiate timing of an electrochemical assay|
|WO2000078992A3 (en)||1999-06-18||2001-07-19||Therasense Inc||Mass transport limited in vivo analyte sensor|
|US6514769B2 (en) *||1999-07-29||2003-02-04||Jin Po Lee||Multiple analyte assay device with sample integrity monitoring system|
|CA2305922C (en)||1999-08-02||2005-09-20||Bayer Corporation||Improved electrochemical sensor design|
|DE19936693A1 (en) *||1999-08-04||2001-02-08||Lre Technology Partner Gmbh||Instrument for the measurement of blood sugar concentrations has a test field with electrodes for the test strip and a circuit for measurement/evaluation of the current strength for display|
|US6352633B1 (en)||1999-08-31||2002-03-05||Spectrumedix Corporation||Automated parallel capillary electrophoresis system with hydrodynamic sample injection|
|WO2001020316A1 (en)||1999-09-13||2001-03-22||Matsushita Electric Industrial Co., Ltd.||Process for producing lipid-modified enzyme and biosensor|
|US6662439B1 (en)||1999-10-04||2003-12-16||Roche Diagnostics Corporation||Laser defined features for patterned laminates and electrodes|
|US6136549A (en)||1999-10-15||2000-10-24||Feistel; Christopher C.||systems and methods for performing magnetic chromatography assays|
|US6283982B1 (en)||1999-10-19||2001-09-04||Facet Technologies, Inc.||Lancing device and method of sample collection|
|US6218571B1 (en)||1999-10-27||2001-04-17||Lifescan, Inc.||8-(anilino)-1-naphthalenesulfonate analogs|
|US6616819B1 (en)||1999-11-04||2003-09-09||Therasense, Inc.||Small volume in vitro analyte sensor and methods|
|DE60106228T2 (en)||2000-03-22||2005-10-13||All Medicus Co., Ltd.||An electrochemical biosensor test strip used with detection electrode and readout meter, the test strip these|
|US6923894B2 (en)||1999-11-11||2005-08-02||Apex Biotechnology Corporation||Biosensor with multiple sampling ways|
|US6875327B1 (en)||1999-11-15||2005-04-05||Matsushita Electric Industrial Co., Ltd.||Biosensor, method of forming thin-film electrode, and method and apparatus for quantitative determination|
|DE60025751T2 (en)||1999-11-15||2006-10-12||Arkray, Inc.||biosensor|
|DE60011286T2 (en)||1999-11-15||2005-07-14||Therasense, Inc., Alameda||Transition metal complex compounds with a bidentate ligands containing an imidazole ring|
|EP1235069B1 (en)||1999-11-16||2006-06-28||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|CA2356364C (en) *||1999-11-22||2003-12-09||Matsushita Electric Industrial Co., Ltd.||Cholesterol sensor and method for determining cholesterol|
|JP4050434B2 (en)||1999-11-29||2008-02-20||アークレイ株式会社||Discrimination method of sample|
|JP2001159618A (en) *||1999-12-03||2001-06-12||Matsushita Electric Ind Co Ltd||Biosensor|
|US6413395B1 (en)||1999-12-16||2002-07-02||Roche Diagnostics Corporation||Biosensor apparatus|
|US6316264B1 (en)||1999-12-17||2001-11-13||Bayer Corporation||Test strip for the assay of an analyte in a liquid sample|
|US6541216B1 (en)||1999-12-22||2003-04-01||Roche Diagnostics Corporation||Amperometric biosensor test strip|
|US6627057B1 (en)||1999-12-23||2003-09-30||Roche Diagnostic Corporation||Microsphere containing sensor|
|DE60019547T2 (en)||1999-12-27||2005-10-06||Matsushita Electric Industrial Co., Ltd., Kadoma||biosensor|
|JP2001183330A (en)||1999-12-27||2001-07-06||Matsushita Electric Ind Co Ltd||Biosensor|
|JP3982133B2 (en)||2000-01-25||2007-09-26||松下電器産業株式会社||Measuring apparatus and a biosensor and dedicated standard solution used therein was used biosensor|
|US6475372B1 (en)||2000-02-02||2002-11-05||Lifescan, Inc.||Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations|
|US6485923B1 (en)||2000-02-02||2002-11-26||Lifescan, Inc.||Reagent test strip for analyte determination having hemolyzing agent|
|US6716577B1 (en)||2000-02-02||2004-04-06||Lifescan, Inc.||Electrochemical test strip for use in analyte determination|
|CN1153968C (en)||2000-02-18||2004-06-16||松下电器产业株式会社||Measurement system|
|EP1172651B1 (en)||2000-02-18||2015-07-15||Panasonic Healthcare Co., Ltd.||Measuring system|
|WO2001061342A1 (en)||2000-02-18||2001-08-23||Matsushita Electric Industrial Co., Ltd.||Inspection chip for sensor measuring instrument|
|US6538735B1 (en)||2000-02-25||2003-03-25||Packard Instrument Company||Method and apparatus for producing and measuring light and for determining the amounts of analytes in microplate wells|
|US6706159B2 (en)||2000-03-02||2004-03-16||Diabetes Diagnostics||Combined lancet and electrochemical analyte-testing apparatus|
|GB0005564D0 (en)||2000-03-08||2000-05-03||Inverness Medical Ltd||Measurjement of substances in liquid|
|JP3985417B2 (en)||2000-03-08||2007-10-03||松下電器産業株式会社||Biosensor and a method of manufacturing the same|
|CA2403481A1 (en)||2000-03-22||2001-09-27||Allmedicus Co., Ltd.||Electrochemical biosensor readout meter|
|DE10014724A1 (en)||2000-03-24||2001-09-27||Endress Hauser Gmbh Co||Liquid level and density monitoring method employed in food, chemical industry, involves evaluating vibration of vibrating rods arranged immersed in liquid at two different modes and recognizing mass change in rods|
|US6571651B1 (en)||2000-03-27||2003-06-03||Lifescan, Inc.||Method of preventing short sampling of a capillary or wicking fill device|
|US6612111B1 (en)||2000-03-27||2003-09-02||Lifescan, Inc.||Method and device for sampling and analyzing interstitial fluid and whole blood samples|
|US20020092612A1 (en)||2000-03-28||2002-07-18||Davies Oliver William Hardwicke||Rapid response glucose sensor|
|ES2312719T3 (en)||2000-03-28||2009-03-01||Diabetes Diagnostics, Inc.||Glucose meter with fast response sensor.|
|CA2404421A1 (en)||2000-03-28||2001-10-04||Lifescan, Inc.||Reagent systems for detecting the presence of a reduced cofactor in a sample and methods for using the same|
|EP1666605A1 (en)||2000-03-28||2006-06-07||Diabetes Diagnostics, Inc.||Continuous process for manufacture of disposable electro-chemical sensor|
|WO2001073419A1 (en)||2000-03-29||2001-10-04||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|WO2001073420A1 (en)||2000-03-30||2001-10-04||Matsushita Electric Industrial Co., Ltd.||Biosensor measuring device|
|JP4679784B2 (en)||2000-03-31||2011-04-27||ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ．||Conductive pattern for monitoring the filling of the sample in a medical device|
|US6488827B1 (en)||2000-03-31||2002-12-03||Lifescan, Inc.||Capillary flow control in a medical diagnostic device|
|US6858433B1 (en)||2000-04-03||2005-02-22||Roche Diagnostics Operations, Inc.||Biosensor electromagnetic noise cancellation|
|US6623501B2 (en)||2000-04-05||2003-09-23||Therasense, Inc.||Reusable ceramic skin-piercing device|
|US6716620B2 (en)||2000-04-17||2004-04-06||Purdue Research Foundation||Biosensor and related method|
|US6413213B1 (en)||2000-04-18||2002-07-02||Roche Diagnostics Corporation||Subscription based monitoring system and method|
|DE60127609D1 (en)||2000-05-08||2007-05-16||Menarini Farma Ind||A device for measurement and control of the content of glucose, lactate or other metabolites in biological fluids|
|JP4562854B2 (en)||2000-05-08||2010-10-13||パナソニック株式会社||Chromatography measurement method|
|WO2001088524A1 (en)||2000-05-12||2001-11-22||Therasense, Inc.||Electrodes with multilayer membranes and methods of using and making the electrodes|
|EP1156302B1 (en)||2000-05-15||2004-09-29||KROHNE MESSTECHNIK GMBH & CO. KG||Level measuring device|
|US6557427B2 (en) *||2000-05-24||2003-05-06||Micronics, Inc.||Capillaries for fluid movement within microfluidic channels|
|DE60121404D1 (en)||2000-05-26||2006-08-24||Matsushita Electric Ind Co Ltd||Biosensor|
|CN1189751C (en)||2000-05-29||2005-02-16||松下电器产业株式会社||Biosensor and method for its preparation|
|DE60133982D1 (en)||2000-06-01||2008-06-26||Matsushita Electric Ind Co Ltd||Biosensor and method for analyzing of blood components|
|US6723371B2 (en) *||2000-06-01||2004-04-20||Bioptik Technology, Inc.||Process for preparing an electrochemical test strip|
|JP2004501380A (en) *||2000-06-26||2004-01-15||ボストン メディカル テクノロジーズ インコーポレイテッド||Glucose measurement system|
|US6591125B1 (en)||2000-06-27||2003-07-08||Therasense, Inc.||Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator|
|EP1296141B1 (en)||2000-06-28||2010-06-16||Panasonic Corporation||Biosensor|
|DE10032775B4 (en) *||2000-07-06||2007-06-14||Endress + Hauser Gmbh + Co. Kg||Device for determining and / or monitoring the fill level of a product in a container|
|US6561989B2 (en) *||2000-07-10||2003-05-13||Bayer Healthcare, Llc||Thin lance and test sensor having same|
|US6444115B1 (en)||2000-07-14||2002-09-03||Lifescan, Inc.||Electrochemical method for measuring chemical reaction rates|
|US6833110B2 (en)||2000-07-20||2004-12-21||Hypoguard Limited||Test member|
|GB0017738D0 (en)||2000-07-20||2000-09-06||Hypoguard Limited||Test member|
|GB0017737D0 (en)||2000-07-20||2000-09-06||Hypoguard Limited||Test device|
|US6885196B2 (en) *||2000-07-24||2005-04-26||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|DE60119133T2 (en)||2000-07-31||2007-01-25||Matsushita Electric Industrial Co., Ltd., Kadoma||biosensor|
|EP1305607A1 (en)||2000-07-31||2003-05-02||Lifescan, Inc.||Method and apparatus for detecting the presence of a fluid on a test strip|
|WO2002010735A1 (en)||2000-07-31||2002-02-07||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|GB0019694D0 (en)||2000-08-11||2000-09-27||Cambridge Sensors Ltd||Electrochemical strip test for small volumes|
|JP3913454B2 (en)||2000-08-29||2007-05-09||三菱電機株式会社||Method of measuring the surface leakage current of the sample|
|US6420128B1 (en)||2000-09-12||2002-07-16||Lifescan, Inc.||Test strips for detecting the presence of a reduced cofactor in a sample and method for using the same|
|US6555061B1 (en)||2000-10-05||2003-04-29||Lifescan, Inc.||Multi-layer reagent test strip|
|US6645359B1 (en)||2000-10-06||2003-11-11||Roche Diagnostics Corporation||Biosensor|
|US6540890B1 (en)||2000-11-01||2003-04-01||Roche Diagnostics Corporation||Biosensor|
|CN100510732C (en)||2000-11-30||2009-07-08||松下电器产业株式会社||Biosensor and measuring instrument for biosensor|
|US6967105B2 (en)||2000-12-02||2005-11-22||Queststar Medical, Inc.||Surface-modified wick for diagnostic test strip|
|EP1358005B1 (en)||2000-12-04||2006-12-27||Kubota Corporation||Air diffuser and flushing method thereof|
|US6447657B1 (en)||2000-12-04||2002-09-10||Roche Diagnostics Corporation||Biosensor|
|US6800488B2 (en)||2000-12-13||2004-10-05||Lifescan, Inc.||Methods of manufacturing reagent test strips|
|GB0030929D0 (en)||2000-12-19||2001-01-31||Inverness Medical Ltd||Analyte measurement|
|US6558528B1 (en)||2000-12-20||2003-05-06||Lifescan, Inc.||Electrochemical test strip cards that include an integral dessicant|
|US6512986B1 (en) *||2000-12-30||2003-01-28||Lifescan, Inc.||Method for automated exception-based quality control compliance for point-of-care devices|
|US6560471B1 (en)||2001-01-02||2003-05-06||Therasense, Inc.||Analyte monitoring device and methods of use|
|RU2180514C1 (en)||2001-01-15||2002-03-20||ШМЕЛЕВ Владимир Михайлович||Method for determining glucose concentration in noninvasive way|
|JP3972063B2 (en) *||2001-01-17||2007-09-05||アークレイ株式会社||Quantitative analysis method and quantitative analysis apparatus using sensors|
|JP2004526482A (en)||2001-02-05||2004-09-02||グルコセンス、インコーポレイテッド||The method of determining the blood glucose concentration|
|US6562625B2 (en)||2001-02-28||2003-05-13||Home Diagnostics, Inc.||Distinguishing test types through spectral analysis|
|US6541266B2 (en)||2001-02-28||2003-04-01||Home Diagnostics, Inc.||Method for determining concentration of an analyte in a test strip|
|US6525330B2 (en) *||2001-02-28||2003-02-25||Home Diagnostics, Inc.||Method of strip insertion detection|
|US20020133064A1 (en)||2001-03-14||2002-09-19||Matsushita Electric Industrial Co., Ltd.||Blood sugar lever measuring device and semiconductor integrated circuit|
|US6576102B1 (en)||2001-03-23||2003-06-10||Virotek, L.L.C.||Electrochemical sensor and method thereof|
|US7124095B2 (en)||2001-03-26||2006-10-17||International Business Machines Corporation||Third party merchandise return method, storage medium and implementing system|
|KR100893275B1 (en)||2001-03-29||2003-10-08||라이프스캔 스코트랜드 리미티드||Integrated sample testing meter|
|WO2002078512A8 (en)||2001-04-02||2004-12-02||Therasense Inc||Blood glucose tracking apparatus and methods|
|EP1281955B1 (en) *||2001-04-16||2013-06-05||Panasonic Corporation||Biosensor|
|DE10123259A1 (en)||2001-05-12||2002-11-21||Eppendorf Ag||Microfluidic storage and / or proportioning|
|EP1308720B1 (en)||2001-05-15||2005-08-24||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|US6932894B2 (en)||2001-05-15||2005-08-23||Therasense, Inc.||Biosensor membranes composed of polymers containing heterocyclic nitrogens|
|US6491803B1 (en)||2001-05-18||2002-12-10||Apex Biotechnology Corporation||Test strip and biosensor incorporating with nanometer metal particles|
|EP1262769B1 (en) *||2001-05-21||2010-12-29||Bayer Corporation||Improved electrochemical sensor|
|US6549796B2 (en)||2001-05-25||2003-04-15||Lifescan, Inc.||Monitoring analyte concentration using minimally invasive devices|
|EP1288654B1 (en) *||2001-05-29||2008-10-22||Matsushita Electric Industrial Co., Ltd.||Biosensor|
|US6960287B2 (en) *||2001-06-11||2005-11-01||Bayer Corporation||Underfill detection system for a test sensor|
|US7226461B2 (en)||2002-04-19||2007-06-05||Pelikan Technologies, Inc.||Method and apparatus for a multi-use body fluid sampling device with sterility barrier release|
|US6501976B1 (en)||2001-06-12||2002-12-31||Lifescan, Inc.||Percutaneous biological fluid sampling and analyte measurement devices and methods|
|EP1398626A4 (en)||2001-06-14||2004-09-22||Matsushita Electric Ind Co Ltd||Biosensor|
|US6576416B2 (en)||2001-06-19||2003-06-10||Lifescan, Inc.||Analyte measurement device and method of use|
|KR100426638B1 (en) *||2001-07-07||2004-04-08||주식회사 인포피아||Glucose strip sensor and glucose measurement method by the strip sensor|
|ES2349451T3 (en)||2001-07-13||2011-01-03||Exxonmobil Research And Engineering Company||Direct production of Fischer-Tropsch wax of high purity.|
|US6767441B1 (en)||2001-07-31||2004-07-27||Nova Biomedical Corporation||Biosensor with peroxidase enzyme|
|CN100374851C (en)||2001-08-01||2008-03-12||爱科来株式会社||Analyzing implements, analyzing device, and method of manufacturing analyzing implement|
|US20030036202A1 (en) *||2001-08-01||2003-02-20||Maria Teodorcyzk||Methods and devices for use in analyte concentration determination assays|
|DE60218695D1 (en)||2001-08-09||2007-04-19||Matsushita Electric Ind Co Ltd||Biosensors and measurement methods|
|CN1279357C (en)||2001-08-10||2006-10-11||松下电器产业株式会社||Biosensor and method for analyzing blood components using it|
|US6814844B2 (en)||2001-08-29||2004-11-09||Roche Diagnostics Corporation||Biosensor with code pattern|
|US7052591B2 (en)||2001-09-21||2006-05-30||Therasense, Inc.||Electrodeposition of redox polymers and co-electrodeposition of enzymes by coordinative crosslinking|
|US7491303B2 (en)||2001-09-28||2009-02-17||Arkray, Inc.||Measuring instrument and concentration measuring device|
|WO2003030731A3 (en)||2001-10-09||2003-12-04||James R Braig||Method and apparatus for improving clinical accuracy of analyte measurements|
|CN1232818C (en)||2001-10-10||2005-12-21||生命扫描有限公司||Electrochemical cell|
|US6797150B2 (en)||2001-10-10||2004-09-28||Lifescan, Inc.||Determination of sample volume adequacy in biosensor devices|
|US7048262B2 (en)||2001-11-01||2006-05-23||Praxair Technology, Inc.||Method and apparatus for injecting oxygen into fermentation processes|
|US6717024B2 (en)||2001-11-06||2004-04-06||Exxonmobil Research And Engineering Company||Slurry hydrocarbon synthesis with liquid hydroisomerization in the synthesis reactor|
|EP1445605A4 (en)||2001-11-14||2005-01-12||Matsushita Electric Ind Co Ltd||Biosensor|
|EP1452857A4 (en)||2001-11-14||2006-05-24||Matsushita Electric Ind Co Ltd||Biosensor|
|US7276146B2 (en)||2001-11-16||2007-10-02||Roche Diagnostics Operations, Inc.||Electrodes, methods, apparatuses comprising micro-electrode arrays|
|US6872298B2 (en) *||2001-11-20||2005-03-29||Lifescan, Inc.||Determination of sample volume adequacy in biosensor devices|
|WO2003045235A1 (en)||2001-11-21||2003-06-05||Optiscan Biomedical Corporation||Method for adjusting a blood analyte measurement|
|US6689411B2 (en) *||2001-11-28||2004-02-10||Lifescan, Inc.||Solution striping system|
|US6749887B1 (en)||2001-11-28||2004-06-15||Lifescan, Inc.||Solution drying system|
|US6872299B2 (en)||2001-12-10||2005-03-29||Lifescan, Inc.||Passive sample detection to initiate timing of an assay|
|US6856125B2 (en)||2001-12-12||2005-02-15||Lifescan, Inc.||Biosensor apparatus and method with sample type and volume detection|
|KR20040077722A (en)||2002-01-15||2004-09-06||아가매트릭스, 인코포레이티드||Method and apparatus for processing electrochemical signals|
|US6863800B2 (en)||2002-02-01||2005-03-08||Abbott Laboratories||Electrochemical biosensor strip for analysis of liquid samples|
|KR20040103928A (en)||2002-02-10||2004-12-09||아가매트릭스, 인코포레이티드||Method and apparatus for assay of electrochemical properties|
|DE10206824B4 (en)||2002-02-18||2005-04-28||Kautex Textron Gmbh & Co Kg||Method for the optical determination level in liquid-filled containers|
|CA2422206C (en)||2002-03-15||2011-06-14||Tyco Telecommunications (Us) Inc.||Hybrid raman/erbium-doped fiber amplifier and transmission system with dispersion map|
|GB0207609D0 (en)||2002-04-02||2002-05-15||Inverness Medical Ltd||Test strip vial|
|GB2388898B (en)||2002-04-02||2005-10-05||Inverness Medical Ltd||Integrated sample testing meter|
|US6909791B2 (en)||2002-04-03||2005-06-21||General Phosphorix, Llc||Method of measuring a line edge roughness of micro objects in scanning microscopes|
|US6743635B2 (en) *||2002-04-25||2004-06-01||Home Diagnostics, Inc.||System and methods for blood glucose sensing|
|US20030143113A2 (en)||2002-05-09||2003-07-31||Lifescan, Inc.||Physiological sample collection devices and methods of using the same|
|CN1467496A (en) *||2002-06-03||2004-01-14||松下电器产业株式会社||biological sensor|
|DE10397017A5 (en)||2002-07-02||2015-05-28||Panasonic Healthcare Holdings Co., Ltd.||Biosensor, biosensor chip and biosensor|
|US7244264B2 (en)||2002-12-03||2007-07-17||Roche Diagnostics Operations, Inc.||Dual blade lancing test strip|
|US6797039B2 (en)||2002-12-27||2004-09-28||Dwain F. Spencer||Methods and systems for selectively separating CO2 from a multicomponent gaseous stream|
|US7452457B2 (en) *||2003-06-20||2008-11-18||Roche Diagnostics Operations, Inc.||System and method for analyte measurement using dose sufficiency electrodes|
|US7488601B2 (en)||2003-06-20||2009-02-10||Roche Diagnostic Operations, Inc.||System and method for determining an abused sensor during analyte measurement|
|US7429865B2 (en)||2005-10-05||2008-09-30||Roche Diagnostics Operations, Inc.||Method and system for error checking an electrochemical sensor|
Also Published As
|Publication number||Publication date||Type|
|US6837976B2 (en)||Disposable sensor with enhanced sample port inlet|
|US20090301899A1 (en)||System and method for measuring an analyte in a sample|
|US20050059872A1 (en)||Electrically-conductive patterns for monitoring the filling of medical devices|
|US20070235346A1 (en)||System and methods for providing corrected analyte concentration measurements|
|US6872299B2 (en)||Passive sample detection to initiate timing of an assay|
|EP1742045A1 (en)||Method for measuring blood components and biosensor and measuring instrument for use therein|
|US20070227912A1 (en)||Methods And Apparatus For Analyzing A Sample In The Presence Of Interferents|
|US6872298B2 (en)||Determination of sample volume adequacy in biosensor devices|
|US20070056858A1 (en)||In vitro analyte sensor, and methods|
|US20090184004A1 (en)||System and method for measuring an analyte in a sample|
|US20100170807A1 (en)||System and method for determining the concentration of an analyte in a sample fluid|
|US6797150B2 (en)||Determination of sample volume adequacy in biosensor devices|
|US6193873B1 (en)||Sample detection to initiate timing of an electrochemical assay|
|US20090236237A1 (en)||Liquid sample measurement method and apparatus|
|US20090194432A1 (en)||System and Methods for Determination of Analyte Concentration Using Time Resolved Amperometry|
|EP1770396A2 (en)||Method and apparatus for rapid electrochemical analysis|
|WO2006110504A1 (en)||Oxidizable species as an internal reference in control solutions for biosensors|
|US20090177406A1 (en)||Slope-Based Compensation|
|WO2004113910A1 (en)||Devices and methods relating to electrochemical biosensors|
|US20080000780A1 (en)||Rapid analyte measurement assay|
|US20080149480A1 (en)||Gel formation to reduce hematocrit sensitivity in electrochemical test|
|JP2003114214A (en)||Method and device for use in analyte concentration determing assay|
|JP2003513279A (en)||How to analyte sensors and associated outside small volume vivo|
|JP2007271623A (en)||System and method for discriminating control solution from physiological sample|
|US20090101523A1 (en)||System and Methods for Determination of Analyte Concentration Using Time Resolved Amperometry|